High-yield algorithms, recognition patterns, and exam traps — built for rapid last-minute recall.
Vignette — A 22-year-old woman presents to the ED with worsening shortness of breath for 3 hours. She has recurrent episodes triggered by exercise, cold air, and viral infections. Today she is wheezing, speaking in short sentences, using accessory muscles, RR 28/min, HR 110/min, SpO2 91% on room air, and her salbutamol inhaler has not helped. Recognition Pattern — Asthma questions usually start with episodic wheeze and reversible obstruction, then test severity grading, acute-exacerbation escalation, controller therapy, or the asthma-vs-COPD discriminator.
Young patient + episodic wheeze + nocturnal/early morning symptoms + triggers + bronchodilator response = asthma. In an acute attack, severity is judged by speech, RR, HR, SpO2, exhaustion, silent chest, and PaCO2 trend.
Asthma is variable airway obstruction: bronchial smooth-muscle constriction, airway edema, mucus plugging, and eosinophilic/type-2 inflammation create episodic airflow limitation.
Reversibility is the discriminator: improvement in FEV1 after bronchodilator supports asthma; fixed post-bronchodilator obstruction in an older smoker points toward COPD.
Silent chest is not improvement: it means critically reduced airflow, fatigue, and impending respiratory arrest.
Normal or rising PaCO2 during severe asthma is dangerous: early asthma causes hypocapnia from hyperventilation; PaCO2 normalizing upward means ventilatory failure is developing.
Controllers prevent risk, relievers rescue symptoms: inhaled corticosteroids reduce airway inflammation and future exacerbation risk; SABA alone relieves bronchospasm but does not treat inflammation.
| STANDARD NAME | SYNONYMS | USED IN |
|---|---|---|
| Asthma | Bronchial asthma, reversible airway disease | Episodic wheeze, cough, dyspnea, chest tightness |
| SABA | Salbutamol, albuterol, blue inhaler | Rapid symptom relief |
| ICS | Inhaled corticosteroid, budesonide, beclomethasone, fluticasone | Controller therapy |
| ICS-formoterol | Anti-inflammatory reliever, MART/SMART in some regimens | Reliever plus controller logic |
| Severe exacerbation | Acute severe asthma | Short sentences, hypoxia, accessory muscles |
| Life-threatening asthma | Silent chest, confusion, exhaustion, rising PaCO2 | Impending arrest |
| ASTHMA | COPD | VOCAL CORD DYSFUNCTION | |
|---|---|---|---|
| Typical age | Child/young adult | >40 years | Young adult, often anxious/athlete |
| Risk story | Atopy, triggers, nocturnal symptoms | Smoking/biomass exposure | Throat tightness, inspiratory symptoms |
| Pattern | Episodic and variable | Persistent and progressive | Sudden attacks, often exercise/stress |
| Spirometry | Reversible obstruction | Fixed post-BD FEV1/FVC <0.70 | May be normal; inspiratory loop flattening |
| Exam sound | Expiratory wheeze | Reduced breath sounds/prolonged expiration | Inspiratory stridor |
| Trap | SABA-only chronic management | Treat as reversible asthma | Escalate asthma drugs without checking larynx |
Bottom row is the discriminator — the single feature that separates these conditions.
1. Acute asthma: mild to moderate Give inhaled SABA repeatedly and reassess response. Add oxygen if hypoxic; target normal safe saturation rather than ignoring hypoxia. Give systemic corticosteroid early if moderate/severe, poor response, or recent relapse. Measure peak expiratory flow when possible, but do not delay treatment for measurement.
2. Acute asthma: severe Nebulized SABA plus ipratropium. Systemic corticosteroid: oral prednisolone if able, IV steroid if vomiting or very ill. Controlled oxygen and close reassessment of speech, RR, HR, SpO2, work of breathing, and PEF. IV magnesium sulfate if severe or poor response to initial bronchodilator/steroid therapy.
3. Life-threatening or exhausted patient Silent chest, confusion, cyanosis, bradycardia, exhaustion, or rising PaCO2 = ICU/intubation preparation. Call senior airway/ICU help early. Continue bronchodilators and steroids while preparing ventilatory support. Do not be falsely reassured by less wheeze if the patient looks tired or quiet.
4. Chronic controller logic Avoid SABA-only chronic treatment when symptoms recur; add inhaled corticosteroid-containing therapy. Step up when daytime symptoms, night symptoms, reliever use, or exacerbations increase. LABA should not be used without ICS in asthma. Check inhaler technique, adherence, smoking, allergens, occupational exposure, and rhinitis before escalating repeatedly.
TRAP: LABA ALONE LABA without ICS is unsafe in asthma. If the stem says salmeterol/formoterol alone, the exam is testing the mortality trap.
TRAP: SILENT CHEST MEANS IMPROVEMENT Silent chest means airflow is critically low. Treat as life-threatening asthma, not as resolving wheeze.
TRAP: NORMAL PACO2 IS REASSURING In severe asthma, normal or rising PaCO2 suggests fatigue and impending ventilatory failure.
TRAP: ASTHMA VS COPD BY WHEEZE ALONE Both can wheeze. Age, smoking history, symptom variability, atopy, and bronchodilator reversibility are the discriminators.
TRAP: REPEATED SABA WITHOUT CONTROLLER Frequent reliever use means poor control and future exacerbation risk. Add or increase ICS-containing therapy.
TRAP: BETA-BLOCKER OR NSAID TRIGGER IGNORED Bronchospasm after beta-blocker or aspirin/NSAID exposure is a drug-trigger clue; aspirin sensitivity plus nasal polyps suggests AERD/Samter pattern.
| CORRECT PATTERN | TRAP PATTERN | CLUE THAT SEPARATES THEM |
|---|---|---|
| Young atopic patient with episodic nocturnal wheeze -> asthma | COPD | COPD is older, smoking/biomass-linked, persistent, and fixed post-bronchodilator. |
| Silent chest in acute asthma -> life-threatening attack | Improving wheeze | Less wheeze plus exhaustion is worse, not better. |
| Normal/rising PaCO2 in severe asthma -> impending respiratory failure | Normal ABG reassurance | Early severe asthma usually has low PaCO2 from hyperventilation. |
| Frequent SABA use -> add ICS-containing controller | Continue SABA alone | Reliever overuse signals uncontrolled airway inflammation. |
| Severe exacerbation not responding -> IV magnesium sulfate | Theophylline escalation | Theophylline is low-yield/rare due to narrow therapeutic window and interactions. |
| 01 Recognize Episodic wheeze, dyspnea, cough, chest tightness, triggers, nocturnal symptoms. | 02 Confirm Spirometry/PEF variability or bronchodilator reversibility when stable enough. | 03 Grade attack Speech, RR, HR, SpO2, accessory muscles, exhaustion, silent chest, PaCO2. | 04 Treat acute SABA, oxygen if hypoxic, systemic steroid; add ipratropium/magnesium/ICU as severity rises. | 05 Prevent relapse ICS-containing controller, inhaler technique, trigger control, action plan. |
| TRIGGER | Young patient with episodic wheeze, triggers, nocturnal symptoms, and salbutamol use. |
| DISCRIMINATOR | Attack severity is decided by speech, oxygenation, work of breathing, silent chest, and PaCO2 trend. |
| TRAP | LABA alone, SABA-only chronic treatment, silent chest misread as improvement, or COPD chosen because the patient wheezes. |
| ACTION | Treat acute severity immediately, then fix long-term control with ICS-containing therapy. |
| FUTURE ALERT | In asthma MCQs, the stem often gives the diagnosis early; the answer is the severity step or the controller escalation. |
| HOW IT'S TESTED | exam patterns test asthma as acute exacerbation management, asthma-vs-COPD discrimination, preferred corticosteroid/controller therapy, and recognition of life-threatening signs. |
| THE DISGUISE | Asthma may appear as nocturnal cough, exercise-induced breathlessness, seasonal wheeze, or a child/young adult repeatedly using a blue inhaler. |
| DISCRIMINATION REWARDED | The rewarded skill is not naming asthma; it is identifying severity and avoiding unsafe treatment choices such as LABA alone or reassurance from a silent chest. |
EXAM ESSENTIAL Silent chest, exhaustion, confusion, bradycardia, or normal/rising PaCO2 in severe asthma means impending respiratory failure. Do not send this patient home or keep repeating SABA casually.
| >=12% and >=200 mL Typical bronchodilator reversibility threshold supporting asthma | SpO2 <90-92% Concerning hypoxia range in acute asthma, depending on protocol | PaCO2 normal/rising Danger sign in severe asthma |
| IV MgSO4 2 g Common adult severe-exacerbation dose used in emergency protocols | LABA + ICS LABA must be paired with ICS in asthma | SABA overuse Marker of poor control and higher exacerbation risk |
1. Young patient, episodic wheeze, nocturnal cough, reversible obstruction: Answer: Asthma
2. Silent chest in acute asthma: Answer: Life-threatening attack, not improvement
3. Severe asthma with normal/rising PaCO2: Answer: Impending ventilatory failure
4. LABA monotherapy in asthma: Answer: Unsafe; use with ICS
5. Severe attack not responding to SABA/steroids: Answer: Add ipratropium and consider IV magnesium/ICU depending on severity
6. Frequent blue inhaler use: Answer: Poor control; start/step up ICS-containing controller
| TAG | TIER | WHY IT MATTERS |
|---|---|---|
| MedCORE Systems Respiratory notes | Local reference | Base structure and local asthma severity/trap content. |
| QBank asthma items | exam evidence | Acute severe asthma, hypoxic asthma, corticosteroid/controller questions, asthma vs COPD options. |
| GINA 2026 Strategy Report | External verification | Used for current asthma management framing and controller-risk emphasis. |
| Official syllabus/Medicine respiratory scope | Syllabus spine | Respiratory system clinical medicine coverage. |
Bottom line — Asthma = variable/reversible obstruction. Acute exam answer = severity-based escalation. Chronic exam answer = ICS-containing controller, not SABA-only or LABA-only therapy.
60-second discriminator — If the patient is quiet, confused, exhausted, cyanosed, bradycardic, or PaCO2 is normal/rising, treat as life-threatening.
EXAM ESSENTIAL Exam essential: A silent chest is a red flag, not a reassuring finding.
WHY IT MATTERS Future alert: Every asthma answer must pass two checks: is this an acute severity question, or a chronic controller question?
Vignette — A 65-year-old man with a 45 pack-year smoking history presents with worsening dyspnea, increased cough, and purulent sputum for 2 days. He has chronic morning cough and progressive exercise limitation. Exam shows barrel chest, pursed-lip breathing, reduced breath sounds, SpO2 84% on room air, and ABG shows pH 7.28, PaCO2 72 mmHg, PaO2 52 mmHg. Recognition Pattern — COPD questions test fixed airflow obstruction, smoker phenotype recognition, acute exacerbation treatment, controlled oxygen targets, NIV/BiPAP indication, and long-term oxygen criteria.
Older smoker or biomass exposure + chronic progressive dyspnea + chronic cough/sputum + post-bronchodilator FEV1/FVC <0.70 = COPD. Acute drowsiness with respiratory acidosis in COPD = NIV/BiPAP unless contraindicated.
COPD is persistent airflow limitation: chronic airway inflammation causes small-airway narrowing, mucus hypersecretion, loss of elastic recoil, and air trapping.
Chronic bronchitis phenotype: productive cough for months over repeated years; mucus gland hypertrophy and airway inflammation dominate.
Emphysema phenotype: alveolar wall destruction and reduced elastic recoil cause hyperinflation, dyspnea, cachexia, and low DLCO.
Exacerbation physiology: infection or pollutant trigger increases airway inflammation, mucus, V/Q mismatch, hypercapnia, and work of breathing.
Oxygen trap: excessive oxygen can worsen CO2 retention in susceptible COPD patients through V/Q changes, Haldane effect, and reduced hypoxic drive contribution.
Alpha-1 antitrypsin deficiency: young patient, minimal smoking, basilar panacinar emphysema, liver disease.
| STANDARD NAME | SYNONYMS | USED IN |
|---|---|---|
| COPD | Chronic obstructive pulmonary disease | Persistent post-BD obstruction |
| Chronic bronchitis | Blue bloater pattern | Productive cough, frequent infections |
| Emphysema | Pink puffer pattern | Dyspnea, hyperinflation, low DLCO |
| AECOPD | Acute exacerbation of COPD | Worse dyspnea, sputum volume/purulence |
| NIV | BiPAP, non-invasive ventilation | Acidotic hypercapnic respiratory failure |
| LTOT | Long-term oxygen therapy | Chronic severe hypoxemia |
| COPD | ASTHMA | HEART FAILURE | |
|---|---|---|---|
| Typical patient | Older smoker/biomass exposure | Young/atopic, episodic | HTN/IHD, edema, orthopnea |
| Course | Progressive persistent dyspnea | Variable attacks | Fluid-overload episodes |
| Spirometry | Post-BD FEV1/FVC <0.70 | Reversible obstruction | May be restrictive/normal |
| Exam | Pursed lips, barrel chest, quiet breath sounds | Expiratory wheeze | Raised JVP, crackles, edema |
| Acute support | Controlled O2 + NIV if acidotic | SABA/steroid; intubate if failing | Diuretic, nitrates, CPAP |
| Trap | Give high-flow O2 to 100% | LABA alone | Treat pulmonary edema as COPD only |
Bottom row is the discriminator — the single feature that separates these conditions.
1. Acute COPD exacerbation Controlled oxygen with target SpO2 88-92% if at risk of hypercapnia. Nebulized SABA plus SAMA: salbutamol plus ipratropium. Systemic corticosteroid, commonly short-course prednisolone. Antibiotics if sputum is purulent, increased volume, severe exacerbation, or ventilatory support is required.
2. Hypercapnic respiratory failure ABG with low pH and raised PaCO2 = acute-on-chronic hypercapnic respiratory failure. Use NIV/BiPAP first-line if patient is conscious, cooperative, and can protect airway. Intubate if NIV fails, coma, vomiting/aspiration risk, severe hemodynamic instability, or inability to protect airway. Recheck ABG after starting NIV to confirm pH and PaCO2 improvement.
3. Stable COPD Smoking cessation is the most important disease-modifying intervention. Bronchodilator foundation: LAMA or LABA; combine if persistent symptoms. ICS only for frequent exacerbations/eosinophilic phenotype or asthma overlap; not routine for everyone. Pulmonary rehabilitation and vaccination reduce morbidity. Assess inhaler technique before escalating.
4. LTOT and special causes LTOT is for chronic severe resting hypoxemia, not simply dyspnea. Classic criteria: PaO2 <=55 mmHg or SaO2 <=88%, or PaO2 56-59 with cor pulmonale/polycythemia. Consider alpha-1 antitrypsin deficiency in young, non-smoker/minimal smoker, basilar emphysema, or liver disease. Avoid routine theophylline due to narrow therapeutic window and arrhythmia/drug-interaction risk.
TRAP: OXYGEN TO 100% COPD exacerbation with hypercapnia needs controlled oxygen, usually target 88-92%, not indiscriminate high-flow oxygen.
TRAP: INTUBATION BEFORE NIV In acidotic COPD exacerbation, NIV/BiPAP is first-line if no contraindication.
TRAP: STEROIDS FOREVER Systemic steroids are for exacerbations, not chronic stable daily COPD maintenance.
TRAP: ICS FOR EVERY COPD PATIENT ICS is selected for frequent exacerbations/eosinophilic/asthma-overlap phenotypes; it is not universal baseline therapy.
TRAP: HOME OXYGEN FOR BREATHLESSNESS ALONE LTOT requires chronic severe hypoxemia criteria, not just dyspnea on exertion.
TRAP: MISSING ALPHA-1 ANTITRYPSIN Young COPD, minimal smoking, basilar emphysema, or liver disease should trigger A1AT deficiency.
| CORRECT PATTERN | TRAP PATTERN | CLUE THAT SEPARATES THEM |
|---|---|---|
| COPD + pH 7.28 + PaCO2 72 + drowsy but rousable -> NIV/BiPAP | High-flow oxygen alone | Acidotic hypercapnia means ventilatory support, not oxygen alone. |
| SpO2 target in CO2-retaining COPD -> 88-92% | Target 100% | Excess oxygen can worsen CO2 retention. |
| Post-BD FEV1/FVC <0.70 -> COPD | Asthma diagnosis from wheeze alone | Fixed obstruction after bronchodilator is the key. |
| Purulent sputum exacerbation -> antibiotics plus bronchodilator/steroid | Bronchodilator only | Purulence indicates likely bacterial trigger. |
| Young non-smoker with basilar emphysema -> A1AT deficiency | Ordinary smoking COPD | Age and distribution are the clue. |
| 01 Recognize Older smoker/biomass exposure with chronic progressive dyspnea and cough. | 02 Confirm Post-bronchodilator FEV1/FVC <0.70. | 03 Exacerbation Dyspnea, sputum volume, sputum purulence; check SpO2 and ABG. | 04 Support Controlled oxygen 88-92%; NIV if pH low and PaCO2 high. | 05 Prevent Stop smoking, LAMA/LABA, rehab, vaccines, selected ICS, LTOT if criteria. |
| TRIGGER | Smoker over 40 with chronic cough, sputum, progressive dyspnea, barrel chest, low SpO2. |
| DISCRIMINATOR | ABG pH 7.28 with PaCO2 72 changes the question from simple oxygen to NIV/BiPAP. |
| TRAP | Giving high-flow oxygen, skipping NIV, prescribing chronic oral steroids, or giving LTOT without criteria. |
| ACTION | Controlled oxygen, bronchodilator nebulizers, systemic steroid, antibiotics when purulent, NIV for acidotic hypercapnia. |
| FUTURE ALERT | In COPD MCQs, always look for the ABG; pH decides whether this is an NIV question. |
| HOW IT'S TESTED | exam patterns test COPD as spirometry interpretation, oxygen target, NIV decision, LTOT criteria, and asthma-vs-COPD differentiation. |
| THE DISGUISE | The stem may look like generic breathlessness, but smoking history, chronic sputum, post-BD obstruction, and hypercapnic ABG reveal COPD. |
| DISCRIMINATION REWARDED | The rewarded skill is recognizing acidotic hypercapnic failure and choosing NIV with controlled oxygen rather than high-flow oxygen alone. |
EXAM ESSENTIAL COPD exacerbation with drowsiness, pH <7.35, and high PaCO2 is ventilatory failure. Treating with oxygen alone while CO2 rises is the fatal miss.
| FEV1/FVC <0.70 Post-bronchodilator obstruction threshold for COPD | 88-92% Common oxygen target in COPD patients at risk of CO2 retention | pH <7.35 + high PaCO2 Acidotic hypercapnic failure -> NIV if suitable |
| PaO2 <=55 or SaO2 <=88% Classic LTOT threshold | PaO2 56-59 LTOT if cor pulmonale or polycythemia present | <45 years Young COPD clue for alpha-1 antitrypsin deficiency |
1. COPD diagnostic spirometry: Answer: Post-bronchodilator FEV1/FVC <0.70
2. COPD exacerbation oxygen target: Answer: 88-92%
3. COPD, pH 7.28, PaCO2 72, drowsy but rousable: Answer: NIV/BiPAP
4. Young non-smoker with basilar emphysema: Answer: Alpha-1 antitrypsin deficiency
5. Stable COPD most important intervention: Answer: Smoking cessation
6. LTOT is indicated for: Answer: Chronic severe resting hypoxemia, not breathlessness alone
| TAG | TIER | WHY IT MATTERS |
|---|---|---|
| MedCORE Systems Respiratory notes | Local reference | Base COPD phenotype, exacerbation, oxygen target, NIV, LTOT traps. |
| QBank COPD items | exam evidence | COPD respiratory failure, hypoxemia, perioperative COPD, ABG support decisions. |
| GOLD current report | External verification | Used to verify modern COPD framing and management concepts. |
| Official syllabus/Medicine respiratory scope | Syllabus spine | Respiratory clinical medicine coverage. |
Bottom line — COPD = older exposure history + fixed obstruction. Acute acidotic hypercapnia = controlled oxygen plus NIV/BiPAP.
60-second discriminator — If COPD ABG shows low pH and high PaCO2, the answer is usually NIV unless contraindicated.
EXAM ESSENTIAL Exam essential: Oxygen is treatment, but uncontrolled oxygen in CO2-retaining COPD is a trap.
WHY IT MATTERS Future alert: COPD questions pivot on one of three clues: spirometry, oxygen target, or ABG.
Vignette — A 60-year-old man presents with fever, productive cough with rusty sputum, pleuritic chest pain, and right lower-lobe consolidation. Another patient develops fever, purulent secretions, and a new infiltrate 72 hours after hospital admission. A severe pneumonia patient has PaO2 50 mmHg on room air, and PaO2 rises only minimally despite 100% oxygen. Recognition Pattern — Pneumonia questions test the diagnosis by infiltrate plus symptoms, then pivot to CAP vs HAP, organism clues, CURB-65/severity, empiric antibiotic logic, aspiration, and the shunt mechanism of refractory hypoxemia.
Fever + cough + new infiltrate = pneumonia. Rusty sputum/lobar consolidation = Streptococcus pneumoniae. Onset >=48 hours after admission = HAP. PaO2 that fails to improve with 100% O2 = intrapulmonary shunt.
CAP: infection acquired outside hospital; most classic exam organism is Streptococcus pneumoniae.
HAP: pneumonia beginning at least 48 hours after admission; concern shifts toward gram-negatives and MRSA depending on risk.
Consolidation: alveoli fill with inflammatory exudate, causing dullness, bronchial breath sounds, increased tactile fremitus, and reduced ventilation.
Shunt physiology: perfusion continues through non-ventilated consolidated lung, so oxygen cannot fully correct the hypoxemia.
Aspiration: dependent-lobe infection or chemical pneumonitis after impaired consciousness, seizures, stroke, vomiting, or hydrocarbon ingestion.
Atypical pneumonia: dry cough, extrapulmonary clues, patchy infiltrates, and milder chest findings than symptoms suggest.
| STANDARD NAME | SYNONYMS | USED IN |
|---|---|---|
| CAP | Community-acquired pneumonia | Before admission or early after arrival |
| HAP | Hospital-acquired pneumonia | >=48 h after admission |
| VAP | Ventilator-associated pneumonia | After intubation/ventilation |
| Atypical pneumonia | Mycoplasma, Legionella, Chlamydophila | Dry cough, systemic/extrapulmonary features |
| Aspiration pneumonia | Dependent-lobe pneumonia | Alcohol, seizures, stroke, reduced consciousness |
| Intrapulmonary shunt | Refractory hypoxemia | PaO2 poor response to 100% O2 |
| STREP PNEUMONIAE | H. INFLUENZAE | KLEBSIELLA | MYCOPLASMA | LEGIONELLA | |
|---|---|---|---|---|---|
| Classic patient | Any age, asplenia | COPD, children | Alcoholic/diabetic | Young adult, close community | Hotel/AC/water exposure |
| Sputum | Rusty | Mucopurulent | Currant jelly | Dry cough | Often dry |
| Lab/culture clue | Lancet GPC, alpha hemolytic | Chocolate agar, X+V | Lactose fermenter | Cold agglutinins | Urine antigen |
| CXR | Lobar consolidation | Bronchopneumonia | Bulging fissure | Patchy bilateral | Patchy/multilobar |
| Trap | Not Mycoplasma as #1 | No growth on blood agar | Mistaken for TB/cancer | Overcalled viral | Hyponatremia/diarrhea missed |
Bottom row is the discriminator — the single feature that separates these conditions.
1. Diagnose and grade severity Confirm compatible symptoms plus new infiltrate on CXR or imaging. Use CURB-65/clinical judgement for home vs ward vs ICU. CURB-65: confusion, urea high, RR >=30, low BP, age >=65. ICU if shock needing vasopressors, respiratory failure needing ventilation, or severe minor-criteria burden.
2. CAP empiric logic Outpatient low-risk: amoxicillin/doxycycline/macrolide depending local pattern. Comorbid/outpatient or inpatient: beta-lactam plus macrolide, or respiratory fluoroquinolone where appropriate. Severe CAP: beta-lactam plus macrolide or beta-lactam plus respiratory fluoroquinolone. Add MRSA/Pseudomonas coverage only when risk factors are present.
3. HAP/VAP logic HAP starts >=48 hours after admission; do not treat as ordinary outpatient CAP. Use local antibiogram and risk factors to choose antipseudomonal beta-lactam coverage. Add MRSA coverage if MRSA risk or high local prevalence. De-escalate once cultures and clinical course clarify the pathogen.
4. Special pivots Post-influenza necrotizing pneumonia -> think Staph aureus/MRSA. Alcoholic with currant-jelly sputum -> Klebsiella. Water exposure + diarrhea + hyponatremia -> Legionella. Kerosene/hydrocarbon ingestion -> do not induce vomiting; watch for aspiration pneumonitis/bronchopneumonia. Refractory hypoxemia despite 100% O2 -> shunt; escalate respiratory support.
TRAP: MYCOPLASMA IS MOST COMMON CAP Strep pneumoniae remains the classic most common CAP answer in the exam banks.
TRAP: NO INFILTRATE, STILL PNEUMONIA Pneumonia diagnosis requires a compatible clinical syndrome plus a new infiltrate or imaging evidence.
TRAP: SHUNT CALLED V/Q MISMATCH If PaO2 barely improves with 100% O2, think shunt, not simple V/Q mismatch.
TRAP: HAP TREATED LIKE OUTPATIENT CAP Timing >=48 hours after admission changes organism coverage.
TRAP: VANCOMYCIN FOR EVERYONE MRSA coverage is risk-based, not automatic for every CAP.
TRAP: INDUCE VOMITING AFTER KEROSENE INGESTION Vomiting increases aspiration risk; supportive care is safer.
| CORRECT PATTERN | TRAP PATTERN | CLUE THAT SEPARATES THEM |
|---|---|---|
| Most common CAP organism -> Strep pneumoniae | Mycoplasma or H. influenzae | Atypicals are common but not the classic #1 answer. |
| Chocolate agar only -> H. influenzae | Strep pneumoniae | H. influenzae requires X and V factors. |
| PaO2 not improving with 100% O2 -> shunt | V/Q mismatch | V/Q mismatch improves with oxygen; shunt resists correction. |
| >=48 h after admission -> HAP | CAP | Hospital timing changes empiric coverage. |
| Post-flu severe pneumonia -> Staph aureus/MRSA concern | Routine macrolide only | Post-influenza necrotizing pattern is the clue. |
| 01 Confirm Symptoms plus new infiltrate. | 02 Classify CAP vs HAP/VAP by timing and setting. | 03 Grade CURB-65 and clinical severity decide site of care. | 04 Cover Empiric antibiotics based on setting, severity, comorbids, MRSA/Pseudomonas risk. | 05 Reassess Cultures when indicated, oxygen response, complications, de-escalation. |
| TRIGGER | Fever, cough, sputum, pleuritic pain, and new infiltrate. |
| DISCRIMINATOR | Setting/timing decides CAP vs HAP; oxygen response decides shunt vs V/Q mismatch; culture clue identifies organism. |
| TRAP | Calling Mycoplasma most common, treating HAP as CAP, or missing shunt physiology. |
| ACTION | Classify, grade severity, choose empiric antibiotics, and escalate respiratory support if refractory hypoxemia. |
| FUTURE ALERT | Pneumonia MCQs usually reward the organism clue or the management setting, not just the word pneumonia. |
| HOW IT'S TESTED | exam banks repeatedly test most common CAP organism, chocolate agar clue, CURB-65/admission thinking, aspiration complication, and shunt mechanism. |
| THE DISGUISE | The stem may present as microbiology, physiology, emergency management, or hydrocarbon poisoning rather than a plain pneumonia diagnosis. |
| DISCRIMINATION REWARDED | The key is recognizing the single clue that changes the answer: culture medium, admission timing, oxygen nonresponse, or exposure history. |
EXAM ESSENTIAL Severe pneumonia with refractory hypoxemia is not a routine ward pneumonia. Poor oxygen response suggests shunt physiology and need for ventilatory escalation.
| >=48 h Hospital timing threshold for HAP | CURB-65 Confusion, urea, RR, BP, age >=65 | RR >=30 CURB-65 respiratory-rate point |
| Strep pneumoniae Classic most common CAP organism | Chocolate agar H. influenzae culture clue | No PaO2 correction Shunt physiology clue |
1. Most common CAP organism: Answer: Streptococcus pneumoniae
2. Tiny colonies on chocolate agar only: Answer: H. influenzae
3. PaO2 barely rises with 100% oxygen: Answer: Intrapulmonary shunt
4. Pneumonia after 72 h admission: Answer: HAP
5. Alcoholic, currant-jelly sputum: Answer: Klebsiella pneumoniae
6. Water exposure, diarrhea, hyponatremia: Answer: Legionella
| TAG | TIER | WHY IT MATTERS |
|---|---|---|
| Day 29 Pneumonia/TB production | Local production | Existing pneumonia organism, shunt, and TB evidence separated here into pneumonia-specific form. |
| QBank respiratory items | exam evidence | CAP organism, H. influenzae culture, shunt physiology, kerosene aspiration, HAP/CURB-65 items. |
| ATS/IDSA CAP guideline | External verification | Used for modern CAP diagnostic/site-of-care and empiric-treatment framing. |
| Official syllabus/Medicine respiratory scope | Syllabus spine | Respiratory infection coverage. |
Bottom line — Pneumonia = symptoms plus infiltrate. The exam answer usually hides in organism clue, CAP/HAP timing, CURB-65 severity, or shunt physiology.
60-second discriminator — If 100% oxygen barely helps, stop thinking simple V/Q mismatch; this is shunt.
EXAM ESSENTIAL Exam essential: Strep pneumoniae is the classic most common CAP answer; H. influenzae is the chocolate-agar clue.
WHY IT MATTERS Future alert: Pneumonia stems often test microbiology or physiology while pretending to test treatment.
Vignette — A 32-year-old man presents with 6 weeks of cough, fever, night sweats, weight loss, and hemoptysis. CXR shows a right upper-lobe cavitary lesion and sputum AFB is positive. Another patient on anti-tuberculous therapy develops joint pains after 3 weeks; a third develops tingling and burning in both feet after 2 months. Recognition Pattern — TB questions test classic reactivation recognition, primary vs reactivation TB, RHZE/RIPE intensive phase, drug-toxicity matching, Type IV hypersensitivity, BCG limitations, and MDR suspicion.
Chronic cough + fever/night sweats/weight loss + hemoptysis + apical cavitation = pulmonary TB. Active TB treatment starts with RHZE/RIPE, and side effects are tested by symptom matching.
Primary TB: initial infection, often lower/mid-zone parenchymal focus plus hilar nodes; Ghon focus/complex may calcify.
Reactivation TB: delayed reactivation in oxygen-rich apical lung causes upper-lobe cavitation, cough, fever, night sweats, weight loss, and hemoptysis.
Miliary TB: hematogenous dissemination produces diffuse millet-seed nodules and systemic illness.
TB immunity: granuloma and Mantoux/PPD response are Type IV delayed cell-mediated hypersensitivity.
BCG: live attenuated Mycobacterium bovis; strongest protection is against severe childhood TB such as TB meningitis and miliary TB, not reliable adult pulmonary TB prevention.
Drug resistance: previous treatment, treatment interruption, contact with resistant TB, or persistent positivity despite therapy should trigger culture and susceptibility thinking.
| STANDARD NAME | SYNONYMS | USED IN |
|---|---|---|
| RIPE/RHZE | Rifampicin, INH, pyrazinamide, ethambutol | Active TB intensive phase |
| Continuation phase | INH + rifampicin | After intensive phase in drug-susceptible TB |
| AFB smear | Acid-fast bacilli | Rapid infectiousness clue |
| GeneXpert/NAAT | Molecular TB/RIF resistance test | Rapid detection |
| Latent TB | Positive TST/IGRA, no active disease | No symptoms/infiltrate |
| MDR-TB | At least INH + rifampicin resistance | Treatment failure/relapse/contact risk |
| PRIMARY TB | REACTIVATION TB | MILIARY TB | DRUG TOXICITY | |
|---|---|---|---|---|
| Typical clue | Ghon focus + hilar nodes | Apical cavitation | Diffuse millet seed CXR | Symptom after ATT |
| Patient | Child/new infection | Adult, immunosuppressed, prior infection | Immunocompromised/systemic illness | On TB therapy |
| Exam ask | Ghon complex | RIPE/RHZE regimen | Dissemination | Match drug to adverse effect |
| Common trap | Called reactivation | Treated with 2 drugs | Mistaken for metastases | Wrong drug toxicity |
Bottom row is the discriminator — the single feature that separates these conditions.
1. Suspected active pulmonary TB Airborne isolation if infectious pulmonary TB suspected. Send sputum AFB smear/culture and molecular testing where available. Start RHZE/RIPE for active TB once diagnosis is likely/confirmed and public-health pathway is engaged. Notify/report according to local TB program requirements.
2. Drug-susceptible pulmonary TB Classic intensive phase: rifampicin + isoniazid + pyrazinamide + ethambutol for 2 months. Continuation phase classically uses isoniazid + rifampicin for 4 months in uncomplicated drug-susceptible pulmonary TB. Give pyridoxine with INH to reduce neuropathy risk. Use DOT/adherence support where available.
3. Toxicity matching INH -> peripheral neuropathy, hepatitis; prevent neuropathy with pyridoxine. Rifampicin -> orange secretions, hepatitis, drug interactions. Pyrazinamide -> hyperuricemia/gout-like joint pain, hepatitis. Ethambutol -> optic neuritis, red-green color blindness. Jaundice/significant hepatitis -> stop hepatotoxic drugs and manage with TB specialist/local protocol.
4. MDR and special disease MDR-TB = resistance at least to INH and rifampicin. Suspect resistance with previous treatment, poor adherence, contact with MDR-TB, or persistent smear/culture positivity. TB meningitis needs prolonged treatment and adjunctive corticosteroid logic. Latent TB is not treated like active cavitary TB; rule out active disease first.
TRAP: ACTIVE TB GETS ONLY INH + RIFAMPICIN Active pulmonary TB needs four drugs in the intensive phase unless specialist susceptibility-directed regimen says otherwise.
TRAP: TB HYPERSENSITIVITY IS TYPE III TB granuloma and PPD are Type IV delayed cell-mediated hypersensitivity.
TRAP: BCG PREVENTS ALL TB BCG mainly protects children from severe forms like meningitis and miliary TB; adult pulmonary protection is variable.
TRAP: PYRAZINAMIDE VS INH TOXICITY Joint pains/hyperuricemia = pyrazinamide. Peripheral neuropathy = INH.
TRAP: ETHAMBUTOL HEPATITIS Ethambutol is classically optic neuritis/red-green color blindness.
TRAP: LATENT TB TREATED AS ACTIVE TB Latent TB has no active disease; do not use a full active-TB regimen unless active disease is present.
| CORRECT PATTERN | TRAP PATTERN | CLUE THAT SEPARATES THEM |
|---|---|---|
| Cavitary upper-lobe lesion + AFB+ -> RHZE/RIPE | INH + rifampicin only | Active TB begins with four drugs. |
| Joint pain on ATT -> pyrazinamide | INH | Pyrazinamide causes hyperuricemia. |
| Burning feet/neuropathy on ATT -> INH | Ethambutol | INH neuropathy is prevented with pyridoxine. |
| Visual change/red-green color blindness -> ethambutol | Rifampicin | Ethambutol is optic neuritis. |
| Caseating granuloma/PPD -> Type IV | Type III | Cell-mediated delayed hypersensitivity. |
| 01 Recognize Chronic cough, constitutional symptoms, hemoptysis, apical cavitation. | 02 Isolate/test Airborne precautions, AFB smear/culture, NAAT/GeneXpert if available. | 03 Treat RHZE/RIPE intensive phase, then continuation phase for drug-susceptible disease. | 04 Monitor LFTs, vision, neuropathy, uric-acid symptoms, adherence. | 05 Resistant? Prior treatment, contact, nonresponse -> culture/susceptibility and specialist regimen. |
| TRIGGER | Chronic cough, weight loss, night sweats, hemoptysis, apical cavitation, AFB positivity. |
| DISCRIMINATOR | Active TB needs RHZE; toxicity symptoms identify the drug; granuloma/PPD identifies Type IV. |
| TRAP | Two-drug active treatment, BCG overclaim, Type III hypersensitivity, or wrong ATT side effect. |
| ACTION | Isolate, test, start active-TB regimen when indicated, match side effects correctly, and suspect MDR when risk appears. |
| FUTURE ALERT | TB questions often ask the drug or hypersensitivity type after giving the diagnosis for free. |
| HOW IT'S TESTED | exam items test RHZE intensive phase, pyrazinamide joint pain, INH neuropathy, Type IV hypersensitivity, BCG limitations, miliary TB, and MDR definitions. |
| THE DISGUISE | TB appears through side effects, immunology, microbiology, public health, or a CXR pattern rather than a simple diagnosis question. |
| DISCRIMINATION REWARDED | The rewarded skill is linking one clue to one rule: active TB = four drugs, joint pain = pyrazinamide, neuropathy = INH, optic neuritis = ethambutol. |
EXAM ESSENTIAL Starting active cavitary TB on an inadequate regimen risks treatment failure and resistance. Active TB is not a two-drug disease at the start.
| 2 months Classic RHZE/RIPE intensive phase | 4 months Classic INH + rifampicin continuation phase | 6 months Classic total uncomplicated drug-susceptible pulmonary TB duration |
| Type IV TB granuloma and PPD hypersensitivity | INH + RIF resistance MDR-TB definition core | BCG Protects best against severe childhood TB forms |
1. Active pulmonary TB intensive phase: Answer: Rifampicin + INH + pyrazinamide + ethambutol
2. ATT joint pains/hyperuricemia: Answer: Pyrazinamide
3. ATT peripheral neuropathy: Answer: INH; give pyridoxine
4. ATT optic neuritis/red-green blindness: Answer: Ethambutol
5. TB granuloma/PPD hypersensitivity: Answer: Type IV
6. BCG best prevents: Answer: Miliary TB and TB meningitis in children
| TAG | TIER | WHY IT MATTERS |
|---|---|---|
| MedCORE Systems Respiratory notes | Local reference | Base TB recognition, RHZE, toxicity, BCG, and pattern content. |
| QBank TB items | exam evidence | TB regimen, pyrazinamide-gout, INH neuropathy, Type IV hypersensitivity, BCG limitations. |
| CDC TB treatment page | External verification | Used for current TB treatment/adherence framing. |
| Official syllabus/Medicine respiratory scope | Syllabus spine | Respiratory infection and TB coverage. |
Bottom line — TB = chronic constitutional cough plus apical/cavitary clues. Active TB starts with RHZE; side effects are the easy marks.
60-second discriminator — Joint pain = pyrazinamide. Neuropathy = INH. Vision = ethambutol. Orange secretions/drug interactions = rifampicin.
EXAM ESSENTIAL Exam essential: Active TB gets four drugs initially; latent TB does not.
WHY IT MATTERS Future alert: If the stem says ATT plus a symptom, stop diagnosing TB and identify the drug toxicity.
Vignette — A 55-year-old man presents with progressive dyspnea and right-sided pleuritic chest discomfort. Exam shows reduced chest expansion, stony dull percussion note, reduced breath sounds, and reduced vocal fremitus at the right base. CXR shows a meniscus sign with blunting of the costophrenic angle. Recognition Pattern — Pleural effusion questions test recognition from exam/CXR, transudate vs exudate classification, Light criteria, and when diagnostic thoracentesis or cytology is needed.
Stony dull percussion + reduced breath sounds + reduced vocal fremitus + meniscus sign = pleural effusion. The next discriminator is transudate vs exudate.
Transudate: systemic pressure problem, usually increased hydrostatic pressure or low oncotic pressure; pleura itself is not primarily inflamed.
Exudate: local pleural disease or inflammation increases capillary permeability; think infection, malignancy, TB, PE, pancreatitis, connective-tissue disease.
Large effusion: compresses lung causing dyspnea, reduced expansion, dullness, and reduced breath sounds.
Empyema: infected pleural fluid; pus, low pH/glucose, high LDH, and systemic toxicity require drainage.
Malignant effusion: recurrent unilateral effusion, weight loss, hemoptysis, smoking history, or cytology-positive fluid.
| STANDARD NAME | SYNONYMS | USED IN |
|---|---|---|
| Transudate | Non-inflammatory pleural fluid | CHF, cirrhosis, nephrotic syndrome |
| Exudate | Inflammatory pleural fluid | Pneumonia, TB, malignancy, PE |
| Light criteria | Protein/LDH criteria | Separates exudate from transudate |
| Parapneumonic effusion | Effusion with pneumonia | May be uncomplicated or complicated |
| Empyema | Pus in pleural space | Fever, toxicity, low pH/glucose |
| Malignant effusion | Cancer-related effusion | Recurrent unilateral effusion |
| TRANSUDATE | EXUDATE | EMPYEMA | |
|---|---|---|---|
| Mechanism | Hydrostatic/oncotic imbalance | Pleural inflammation/permeability | Infected pleural collection |
| Common causes | CHF, cirrhosis, nephrotic syndrome | Pneumonia, TB, malignancy, PE | Complicated pneumonia |
| Fluid protein/LDH | Low | High by Light criteria | Very high LDH, low pH/glucose |
| Management pivot | Treat underlying cause | Diagnostic tap and cause-directed treatment | Drain plus antibiotics |
| Trap | Tap every bilateral CHF effusion | Call all effusions CHF | Antibiotics alone without drainage |
Bottom row is the discriminator — the single feature that separates these conditions.
1. Recognize effusion CXR: costophrenic blunting, meniscus sign; ultrasound confirms and guides tap. Exam: reduced expansion, stony dullness, reduced breath sounds/fremitus. Massive effusion may shift mediastinum away.
2. Diagnostic thoracentesis Tap new unilateral effusion, unexplained effusion, suspected infection/malignancy/TB, or atypical CHF effusion. Send protein, LDH, glucose, pH, cell count, Gram stain/culture, AFB/TB tests when indicated, and cytology if malignancy suspected. Use ultrasound guidance when possible.
3. Light criteria Exudate if pleural/serum protein ratio >0.5. Exudate if pleural/serum LDH ratio >0.6. Exudate if pleural LDH > two-thirds upper limit of normal serum LDH. If any one is positive, classify as exudate.
4. Treat by cause CHF transudate: diuretics and HF treatment. Parapneumonic effusion: antibiotics; drain if complicated or empyema. Malignant recurrent effusion: therapeutic drainage, pleurodesis/indwelling catheter depending setting. TB effusion: anti-TB regimen after diagnosis.
TRAP: PNEUMOTHORAX VS EFFUSION Effusion is stony dull; pneumothorax is hyperresonant. Both can reduce breath sounds.
TRAP: ALL EFFUSIONS NEED ANTIBIOTICS Transudates from CHF/cirrhosis/nephrotic syndrome need underlying-cause treatment, not automatic antibiotics.
TRAP: ALL EFFUSIONS ARE CHF Unilateral, fever, pleuritic pain, weight loss, hemoptysis, or recurrent effusion needs diagnostic workup.
TRAP: EMPYEMA TREATED MEDICALLY ONLY Empyema needs drainage plus antibiotics.
TRAP: LIGHT CRITERIA REQUIRE ALL THREE Any one positive Light criterion classifies the effusion as exudate.
| CORRECT PATTERN | TRAP PATTERN | CLUE THAT SEPARATES THEM |
|---|---|---|
| Stony dullness + meniscus -> pleural effusion | Pneumothorax | Pneumothorax is hyperresonant. |
| New unilateral effusion -> diagnostic thoracentesis | Treat blindly as CHF | Unilateral/new effusion needs explanation. |
| Any Light criterion positive -> exudate | Need all criteria positive | Light criteria are OR logic. |
| Pus/low pH/low glucose -> empyema drainage | Antibiotics alone | Infected pleural space needs source control. |
| 01 Recognize Dullness, reduced breath sounds/fremitus, meniscus. | 02 Image CXR then ultrasound if tap planned. | 03 Tap? New/unilateral/unexplained/infective/malignant suspicion -> thoracentesis. | 04 Classify Light criteria: transudate vs exudate. | 05 Treat Cause-directed; drain empyema/complicated effusion. |
| TRIGGER | Reduced breath sounds with stony dull percussion and meniscus sign. |
| DISCRIMINATOR | Dullness separates effusion from pneumothorax; Light criteria separate exudate from transudate. |
| TRAP | Calling every unilateral effusion CHF or forgetting that one positive Light criterion is enough. |
| ACTION | Recognize, image, tap when indicated, classify, then treat cause. |
| FUTURE ALERT | Pleural effusion MCQs reward the percussion note and Light criteria. |
| HOW IT'S TESTED | exam patterns test effusion vs pneumothorax, pleural tap decisions, malignancy/TB suspicion, and exudate/transudate logic. |
| THE DISGUISE | Often appears as short breathlessness with unilateral chest findings rather than a named effusion. |
| DISCRIMINATION REWARDED | The rewarded clue is stony dullness plus reduced fremitus, then Light criteria. |
EXAM ESSENTIAL Do not miss empyema: infected pleural fluid needs drainage plus antibiotics.
| >0.5 Pleural/serum protein ratio for exudate | >0.6 Pleural/serum LDH ratio for exudate | >2/3 ULN Pleural LDH exudate criterion |
| Any 1 Any one Light criterion positive = exudate | pH <7.2 Complicated parapneumonic effusion/empyema drainage clue |
1. Stony dullness + reduced breath sounds: Answer: Pleural effusion
2. Hyperresonance + reduced breath sounds: Answer: Pneumothorax
3. Any Light criterion positive: Answer: Exudate
4. Pus in pleural space: Answer: Empyema; drain
5. CHF bilateral transudate: Answer: Diuretics/treat HF
| TAG | TIER | WHY IT MATTERS |
|---|---|---|
| Existing Respiratory notes | Local reference | Pleural effusion recognition and trap content. |
| QBank | exam evidence | Pleural effusion vs pneumothorax and pleural tap/cytology items. |
| Guideline gap-check | External verification | Used for thoracentesis and pleural disease framing. |
Bottom line — Effusion is dull; pneumothorax is resonant. Light criteria use OR logic.
60-second discriminator — New unilateral effusion is a diagnostic-tap question until proven otherwise.
EXAM ESSENTIAL Exam essential: Any one Light criterion positive means exudate.
WHY IT MATTERS Future alert: If the stem says stony dullness, do not pick pneumothorax.
Vignette — A young tall man develops sudden pleuritic chest pain and dyspnea. Exam shows reduced breath sounds and hyperresonance on the right. Another patient after chest trauma is hypotensive with distended neck veins, tracheal deviation to the left, and absent right-sided breath sounds. Recognition Pattern — Pneumothorax questions test recognition by hyperresonance and absent breath sounds, then pivot to immediate needle decompression for tension pneumothorax or occlusive dressing/chest tube for open pneumothorax.
Sudden pleuritic chest pain + dyspnea + unilateral reduced breath sounds + hyperresonance = pneumothorax. Add hypotension, JVP, tracheal deviation, shock = tension pneumothorax: treat before CXR.
Simple pneumothorax: air in pleural space collapses lung; pressure is not yet obstructing venous return.
Tension pneumothorax: one-way valve traps air, intrathoracic pressure rises, mediastinum shifts, venous return falls, obstructive shock develops.
Open pneumothorax: chest wall defect allows air to move through wound; may become tension if sealed incorrectly.
Secondary spontaneous pneumothorax: COPD, TB, cystic fibrosis, Pneumocystis, malignancy, or underlying lung disease; less reserve and higher risk.
Iatrogenic pneumothorax: central line, lung biopsy, thoracentesis, mechanical ventilation, or supraclavicular procedures injure pleura.
| STANDARD NAME | SYNONYMS | USED IN |
|---|---|---|
| Primary spontaneous | Tall thin young patient | No known lung disease |
| Secondary spontaneous | COPD/TB/CF/PJP-related | Underlying lung disease |
| Tension pneumothorax | Obstructive shock pneumothorax | Hypotension, JVP, tracheal shift |
| Open pneumothorax | Sucking chest wound | Air enters through wound |
| Hemothorax | Blood in pleural space | Dullness, shock after trauma |
| Needle decompression | Needle thoracostomy | Emergency decompression |
| SIMPLE PNEUMOTHORAX | TENSION PNEUMOTHORAX | OPEN PNEUMOTHORAX | PLEURAL EFFUSION | |
|---|---|---|---|---|
| Percussion | Hyperresonant | Hyperresonant | Hyperresonant around wound | Stony dull |
| Breath sounds | Reduced | Absent/reduced | Reduced | Reduced |
| Hemodynamics | Usually stable | Shock/hypotension | May deteriorate | Usually stable unless massive |
| Key clue | Sudden pleuritic pain | JVP + tracheal deviation | Sucking wound | Meniscus sign |
| Immediate action | CXR/aspiration/chest tube by case | Needle decompression now | Occlusive 3-sided dressing + chest tube | Thoracentesis if indicated |
Bottom row is the discriminator — the single feature that separates these conditions.
1. Tension pneumothorax Do not wait for CXR. Immediate needle decompression. Follow with definitive chest tube. Give oxygen and manage shock/trauma simultaneously.
2. Open pneumothorax Apply occlusive dressing taped on three sides or vented chest seal. Insert chest tube away from wound. Definitive surgical repair after stabilization. Avoid fully sealing without venting if tension risk.
3. Stable spontaneous pneumothorax Assess symptoms, size, oxygenation, and primary vs secondary status. Observation/oxygen may be enough for small stable primary cases. Aspiration or chest tube if large, symptomatic, secondary, or worsening. Admit secondary pneumothorax more readily.
4. Iatrogenic/traumatic Check CXR/ultrasound after risky pleural/central line procedures if symptoms occur. Chest tube for large, symptomatic, ventilated, traumatic, or hemopneumothorax cases. Look for associated rib fracture, lung injury, or great-vessel trauma.
TRAP: CXR BEFORE TENSION TREATMENT Tension pneumothorax is a clinical diagnosis; decompress immediately.
TRAP: PLEURAL EFFUSION VS PNEUMOTHORAX Effusion is dull; pneumothorax is hyperresonant.
TRAP: FULLY SEAL SUCKING WOUND A fully sealed open pneumothorax can convert to tension; use vented/three-sided dressing.
TRAP: NEEDLE ONLY IS DEFINITIVE Needle decompression is temporizing; chest tube follows.
TRAP: SECONDARY PNEUMOTHORAX TREATED CASUALLY Underlying lung disease means less reserve and higher admission/drainage threshold.
| CORRECT PATTERN | TRAP PATTERN | CLUE THAT SEPARATES THEM |
|---|---|---|
| Tension pneumothorax -> needle decompression before CXR | Chest X-ray first | Shock plus tracheal deviation makes this a clinical emergency. |
| Open pneumothorax -> three-sided dressing + chest tube | Completely seal wound only | Must allow air to escape. |
| Hyperresonance -> pneumothorax | Pleural effusion | Effusion is stony dull. |
| Needle decompression -> chest tube next | Needle decompression as final treatment | Needle buys time; tube is definitive. |
| 01 Recognize Sudden pleuritic pain, dyspnea, unilateral absent sounds, hyperresonance. | 02 Unstable? Hypotension, JVP, tracheal deviation -> tension. | 03 Tension Needle decompression immediately, then chest tube. | 04 Open Three-sided/vented dressing, chest tube, surgical repair. | 05 Stable CXR/US, decide observation vs aspiration vs chest tube. |
| TRIGGER | Unilateral absent breath sounds with hyperresonance after sudden dyspnea or trauma. |
| DISCRIMINATOR | Shock/JVP/tracheal deviation converts simple pneumothorax into tension pneumothorax. |
| TRAP | Waiting for imaging or confusing stony dull effusion with hyperresonant pneumothorax. |
| ACTION | Decompress tension immediately; use chest tube for definitive management when indicated. |
| FUTURE ALERT | Pneumothorax questions are usually next-best-step questions, not diagnosis-writing questions. |
| HOW IT'S TESTED | exam banks repeatedly test tension pneumothorax signs and immediate management, open pneumothorax, and effusion vs pneumothorax discrimination. |
| THE DISGUISE | May appear as trauma, central-line complication, asthma/COPD deterioration, or chest pain differential. |
| DISCRIMINATION REWARDED | The key is percussion note plus hemodynamic status. |
EXAM ESSENTIAL Do not send a tension pneumothorax to radiology. Needle decompression comes first.
| 0 min Time to decompression in tension pneumothorax | 3-sided Classic open pneumothorax dressing concept | Chest tube Definitive treatment after needle decompression |
| Hyperresonant Percussion clue for pneumothorax |
1. Tension pneumothorax immediate management: Answer: Needle decompression before CXR
2. Open pneumothorax first dressing: Answer: Three-sided/vented occlusive dressing
3. Pneumothorax percussion note: Answer: Hyperresonant
4. Pleural effusion percussion note: Answer: Stony dull
5. Needle decompression is followed by: Answer: Chest tube
| TAG | TIER | WHY IT MATTERS |
|---|---|---|
| QBank | exam evidence | Multiple tension/open pneumothorax and pleural effusion-vs-pneumothorax items. |
| Respiratory production map | Production spine | High-yield fatal-miss respiratory emergency topic. |
| Guideline gap-check | External verification | Used only for current emergency framing. |
Bottom line — Tension pneumothorax is decompressed before imaging.
60-second discriminator — Hyperresonance + shock + tracheal shift = tension; act now.
EXAM ESSENTIAL Exam essential: Tension pneumothorax is a clinical diagnosis.
WHY IT MATTERS Future alert: If the patient is unstable, the answer is an action, not an investigation.
Vignette — A 65-year-old man with COPD presents with acute-on-chronic dyspnea and purulent sputum. ABG shows pH 7.28, PaO2 48 mmHg, PaCO2 76 mmHg, and HCO3 is elevated. He is drowsy but rousable. Another patient with severe pneumonia has PaO2 50 mmHg and PaCO2 32 mmHg. Recognition Pattern — ABG questions test pH first, then CO2/HCO3 direction, then compensation and support. Respiratory failure questions test Type 1 hypoxemic vs Type 2 hypercapnic failure and NIV/intubation thresholds.
Low PaO2 = respiratory failure. High PaCO2 with acidosis = Type 2 ventilatory failure. COPD with pH <7.35 and high PaCO2 usually needs NIV/BiPAP if suitable.
Type 1 respiratory failure: hypoxemia with normal/low PaCO2; caused by V/Q mismatch, shunt, diffusion defect, pneumonia, PE, pulmonary edema, ARDS.
Type 2 respiratory failure: hypoxemia plus hypercapnia; caused by alveolar hypoventilation such as COPD, CNS depression, neuromuscular disease, chest wall disease.
Acute respiratory acidosis: high PaCO2 lowers pH before kidneys can retain enough bicarbonate.
Chronic respiratory acidosis: kidneys retain bicarbonate, so pH is closer to normal despite high PaCO2.
Metabolic alkalosis with respiratory compensation: vomiting/pyloric stenosis raises HCO3; PaCO2 rises as compensation.
Shunt: severe pneumonia/ARDS produces hypoxemia poorly responsive to oxygen.
| STANDARD NAME | SYNONYMS | USED IN |
|---|---|---|
| Type 1 RF | Hypoxemic respiratory failure | Low PaO2, normal/low PaCO2 |
| Type 2 RF | Hypercapnic respiratory failure | Low PaO2, high PaCO2 |
| NIV | BiPAP | Ventilatory support without intubation |
| Respiratory acidosis | CO2 retention | Low pH + high PaCO2 |
| Metabolic alkalosis | High HCO3 | Vomiting/pyloric stenosis |
| Compensation | Expected physiologic response | Opposite system moves pH toward normal |
| RESP ACIDOSIS | RESP ALKALOSIS | MET ACIDOSIS | MET ALKALOSIS | |
|---|---|---|---|---|
| pH | Low | High | Low | High |
| Primary change | PaCO2 high | PaCO2 low | HCO3 low | HCO3 high |
| Classic cause | COPD/CNS depression | Anxiety/PE/sepsis | DKA/renal failure/diarrhea | Vomiting/pyloric stenosis |
| Compensation | HCO3 rises | HCO3 falls | PaCO2 falls | PaCO2 rises |
| Trap | Miss acute on chronic | Call it metabolic | Ignore anion gap | Call high PaCO2 primary |
Bottom row is the discriminator — the single feature that separates these conditions.
1. ABG interpretation steps Step 1: pH: acidemia or alkalemia. Step 2: PaCO2 and HCO3: which explains the pH? Step 3: compensation: is the other system moving appropriately? Step 4: oxygenation: PaO2/SpO2 and need for oxygen/ventilatory support.
2. Type 1 respiratory failure Give oxygen and treat cause: pneumonia, PE, edema, ARDS, pneumothorax. If oxygenation fails despite high FiO2, think shunt and escalate support. CPAP/HFNC/intubation depends on work of breathing and oxygen response.
3. Type 2 respiratory failure Controlled oxygen if COPD/CO2 retention risk. NIV/BiPAP for acidotic hypercapnic COPD if suitable. Intubate if NIV fails, airway not protected, severe coma, shock, vomiting, or exhaustion. Repeat ABG after support change.
4. Compensation traps Respiratory disorders compensate through kidneys over hours-days. Metabolic disorders compensate through ventilation quickly. Compensation does not overshoot the pH past normal. Mixed disorder if compensation is inappropriate.
TRAP: READ PAO2 FIRST ONLY ABG interpretation starts with pH, then PaCO2/HCO3; oxygenation is a separate severity/support question.
TRAP: COPD HYPERCAPNIA TREATED WITH OXYGEN ALONE Low pH plus high PaCO2 is ventilatory failure; use NIV if suitable.
TRAP: HIGH HCO3 ALWAYS METABOLIC ALKALOSIS High HCO3 may be renal compensation for chronic respiratory acidosis.
TRAP: COMPENSATION OVERCORRECTS Physiologic compensation moves pH toward normal but does not overshoot.
TRAP: REFRACTORY HYPOXEMIA CALLED DIFFUSION DEFECT Poor response to 100% oxygen points to shunt.
| CORRECT PATTERN | TRAP PATTERN | CLUE THAT SEPARATES THEM |
|---|---|---|
| pH low + PaCO2 high -> respiratory acidosis | Metabolic acidosis | CO2 explains the low pH. |
| COPD + pH 7.28 + PaCO2 76 -> NIV | Oxygen alone | This is acidotic hypercapnic respiratory failure. |
| Vomiting + pH high + HCO3 high -> metabolic alkalosis | Respiratory acidosis from high PaCO2 | PaCO2 is compensatory. |
| PaO2 unresponsive to 100% O2 -> shunt | V/Q mismatch | V/Q mismatch improves with oxygen. |
| 01 pH Acidemia or alkalemia. | 02 Primary PaCO2 respiratory; HCO3 metabolic. | 03 Compensated? Other system moving appropriately or mixed disorder? | 04 Oxygenation Type 1 vs Type 2 RF. | 05 Support O2, NIV, CPAP/HFNC, or intubation by pattern. |
| TRIGGER | ABG numbers or a COPD patient with drowsiness and hypercapnia. |
| DISCRIMINATOR | Low pH with high PaCO2 means ventilatory failure; high HCO3 may be compensation. |
| TRAP | Treating ABG as memorization instead of a four-step process. |
| ACTION | Interpret pH, identify primary disorder, assess compensation, then choose oxygen/NIV/intubation. |
| FUTURE ALERT | ABG MCQs are arithmetic-looking, but the answer is usually the support decision. |
| HOW IT'S TESTED | exam items test COPD hypercapnic respiratory failure, pyloric stenosis metabolic alkalosis compensation, pneumonia shunt hypoxemia, and ABG interpretation labels. |
| THE DISGUISE | The question may be filed under physiology, medicine, surgery, or pediatrics depending on the stem. |
| DISCRIMINATION REWARDED | The rewarded skill is pH-first interpretation plus support escalation. |
EXAM ESSENTIAL A drowsy COPD patient with pH <7.35 and high PaCO2 is failing ventilation. Oxygen alone is not enough.
| pH 7.35-7.45 Normal pH range | PaCO2 35-45 Normal PaCO2 range | HCO3 22-26 Normal bicarbonate range |
| PaO2 <60 Common respiratory failure threshold | pH <7.35 + high CO2 Acidotic hypercapnic failure |
1. pH low, PaCO2 high: Answer: Respiratory acidosis
2. pH high, HCO3 high after vomiting: Answer: Metabolic alkalosis with respiratory compensation
3. Type 1 respiratory failure: Answer: Low PaO2, normal/low PaCO2
4. Type 2 respiratory failure: Answer: Low PaO2, high PaCO2
5. COPD acidotic hypercapnia support: Answer: NIV/BiPAP if suitable
| TAG | TIER | WHY IT MATTERS |
|---|---|---|
| Existing Respiratory notes | Local reference | ABG and respiratory failure base content. |
| QBank | exam evidence | COPD ABG support, pyloric stenosis ABG, pneumonia shunt items. |
| Guideline gap-check | External verification | Used for oxygen/NIV framing. |
Bottom line — pH first, PaCO2/HCO3 second, compensation third, support decision fourth.
60-second discriminator — Low pH + high CO2 in COPD = NIV question.
EXAM ESSENTIAL Exam essential: Compensation never overshoots.
WHY IT MATTERS Future alert: The ABG label matters less than the next respiratory support step.
Vignette — A 45-year-old man develops sudden pleuritic chest pain and dyspnea 6 days after a long-haul flight. D-dimer is elevated and CTPA shows a filling defect in the right pulmonary artery. BP is 90/60 mmHg and HR is 125/min. Another young woman on combined oral contraceptive pills presents with sudden dyspnea and pleuritic pain. Recognition Pattern — PE questions test risk factors, sudden pleuritic dyspnea recognition, D-dimer vs CTPA logic, anticoagulation, massive PE thrombolysis, and OCP/VTE contraindication.
Sudden dyspnea + pleuritic chest pain + tachycardia + VTE risk factor = PE until proven otherwise. Hypotension/shock means high-risk/massive PE and changes treatment toward thrombolysis if no contraindication.
PE source: most emboli arise from lower-limb/pelvic DVT.
V/Q mismatch: embolus blocks perfusion to ventilated alveoli, increasing dead space and causing hypoxemia and tachypnea.
Right-heart strain: large clot increases pulmonary vascular resistance, causing RV dilation/failure, hypotension, syncope, and shock.
Risk factors: surgery, immobilization, long-haul flight, malignancy, pregnancy/postpartum, estrogen/OCP, thrombophilia, prior VTE.
D-dimer: sensitive but nonspecific; useful in low/intermediate probability to rule out, not to confirm.
CTPA: typical confirmatory imaging when not contraindicated.
| STANDARD NAME | SYNONYMS | USED IN |
|---|---|---|
| PE | Pulmonary embolism | Sudden dyspnea, pleuritic pain, tachycardia |
| DVT | Deep vein thrombosis | Leg swelling/pain source |
| D-dimer | Fibrin degradation marker | Rule-out in low probability |
| CTPA | CT pulmonary angiography | Filling defect |
| Massive/high-risk PE | PE with hypotension/shock | RV failure/obstructive shock |
| Anticoagulation | LMWH/UFH/DOAC/warfarin pathway | Prevents clot extension |
| LOW PROBABILITY | STABLE CONFIRMED PE | MASSIVE/HIGH-RISK PE | |
|---|---|---|---|
| Clinical state | Mild symptoms, low Wells | Normotensive, CTPA positive | Hypotension/shock/syncope |
| Test pivot | D-dimer rule-out | CTPA confirms | Echo/RV strain may support emergency decision |
| Treatment | No treatment if ruled out | Anticoagulation | Thrombolysis if no contraindication |
| Anticoagulant | None if excluded | DOAC/LMWH/UFH pathway | UFH often if unstable/procedure likely |
| Trap | CTPA for everyone | Thrombolyse stable PE | Delay lysis in shock |
Bottom row is the discriminator — the single feature that separates these conditions.
1. Suspected PE: diagnostic logic Assess pretest probability using Wells/clinical judgement. Low probability: D-dimer can rule out if negative. Intermediate/high or positive D-dimer: CTPA if appropriate. V/Q scan if CTPA contraindicated and chest X-ray suitable.
2. Stable confirmed PE Start anticoagulation unless contraindicated. DOACs are common for stable patients; LMWH useful in pregnancy/cancer contexts depending protocol. Assess bleeding risk and provoking factors. Avoid estrogen-containing contraception after VTE.
3. Massive/high-risk PE Hypotension/shock from PE = reperfusion question. Systemic thrombolysis if no contraindication. Use UFH when rapid reversal/procedures may be needed. Consider embolectomy/catheter therapy if lysis contraindicated or fails.
4. Prevention and recurrence Identify provoking factor: surgery, immobilization, OCP, malignancy, thrombophilia. Duration of anticoagulation depends on provoked vs unprovoked and bleeding risk. Compression/early mobilization/prophylaxis in high-risk hospitalized/surgical patients. Combined OCP is contraindicated after VTE/PE.
TRAP: D-DIMER CONFIRMS PE D-dimer is a rule-out test in low/intermediate probability; positive is nonspecific.
TRAP: THROMBOLYSIS FOR EVERY PE Thrombolysis is for massive/high-risk PE with shock/hypotension or selected deteriorating cases.
TRAP: STABLE PE GETS NO ANTICOAGULATION Anticoagulation is the core treatment for stable confirmed PE.
TRAP: IGNORE OCP HISTORY Estrogen/OCP is a VTE risk factor and becomes contraindicated after PE.
TRAP: PE RULED OUT BY NORMAL CXR CXR can be normal in PE; it mainly helps exclude alternatives and choose V/Q suitability.
| CORRECT PATTERN | TRAP PATTERN | CLUE THAT SEPARATES THEM |
|---|---|---|
| Low probability + negative D-dimer -> PE ruled out | CTPA anyway | D-dimer is used to avoid imaging in low-risk cases. |
| CTPA filling defect, stable -> anticoagulation | Thrombolysis | No shock, no lysis. |
| PE + BP 90/60/shock -> thrombolysis if eligible | Routine anticoagulation only | Hypotension defines high-risk PE. |
| OCP-associated PE -> avoid estrogen contraception | Restart combined OCP | Prior VTE is an estrogen contraindication. |
| 01 Suspect Sudden dyspnea, pleuritic pain, tachycardia, VTE risk. | 02 Probability Wells/clinical probability. | 03 Test D-dimer if low; CTPA if positive/high probability. | 04 Stable? Normotensive -> anticoagulate. | 05 Shock? Hypotension/RV failure -> thrombolysis if eligible. |
| TRIGGER | Sudden pleuritic chest pain and dyspnea after long-haul flight, OCP, surgery, cancer, or immobilization. |
| DISCRIMINATOR | Hemodynamic status decides anticoagulation vs thrombolysis. |
| TRAP | Using D-dimer as confirmation, thrombolysing stable PE, or missing OCP contraindication after VTE. |
| ACTION | Risk-stratify, image appropriately, anticoagulate stable PE, thrombolyse massive PE if eligible. |
| FUTURE ALERT | In PE MCQs, BP is the pivot. |
| HOW IT'S TESTED | exam banks test PE after flight/OCP, CTPA as confirmatory test, D-dimer role, massive PE treatment, and estrogen contraindication. |
| THE DISGUISE | PE may appear as chest pain differential, collapse/shock, OBGYN contraception, or postoperative dyspnea. |
| DISCRIMINATION REWARDED | The rewarded clue is risk factor plus sudden pleuritic dyspnea, then BP. |
EXAM ESSENTIAL Massive PE with hypotension is obstructive shock. Do not manage it like low-risk PE if thrombolysis is indicated and safe.
| BP <90 High-risk/massive PE shock clue | D-dimer Rule-out, not confirmatory | CTPA Common confirmatory imaging test |
| OCP/estrogen VTE risk and contraindicated after PE | 3 months+ Common minimum anticoagulation concept for provoked VTE, protocol-dependent |
1. Sudden pleuritic dyspnea after long flight: Answer: Pulmonary embolism
2. Best confirmatory test in common PE stems: Answer: CT pulmonary angiography
3. Low probability PE with negative D-dimer: Answer: PE ruled out
4. Stable confirmed PE: Answer: Anticoagulation
5. PE with hypotension/shock: Answer: Thrombolysis if eligible
6. PE on combined OCP: Answer: Avoid estrogen-containing contraception
| TAG | TIER | WHY IT MATTERS |
|---|---|---|
| QBank | exam evidence | PE after long-haul flight/OCP, CTPA, massive PE treatment, OCP contraindication. |
| Respiratory production map | Production spine | High-yield respiratory fatal-miss topic. |
| Guideline gap-check | External verification | Used for diagnostic and treatment framing. |
Bottom line — PE = sudden pleuritic dyspnea with VTE risk. Stable = anticoagulate. Shock = thrombolyse if safe.
60-second discriminator — D-dimer rules out; CTPA confirms; BP decides thrombolysis.
EXAM ESSENTIAL Exam essential: In PE, hemodynamic instability is the treatment pivot.
WHY IT MATTERS Future alert: A positive D-dimer is not the diagnosis; it is the bridge to imaging.
Vignette — A 65-year-old smoker presents with 3 months of cough, weight loss, hemoptysis, and a right hilar mass. Serum sodium is low. Another patient with known lung cancer develops progressive back pain, bilateral leg weakness, and urinary retention over 48 hours. Recognition Pattern — Lung cancer questions test smoking red flags, central vs peripheral histology clues, paraneoplastic syndromes, SPN risk stratification, and metastatic spinal cord compression as an emergency.
Older smoker + hemoptysis + weight loss + persistent cough or non-resolving pneumonia = lung cancer until proven otherwise. Back pain + weakness + urinary retention in known cancer = metastatic cord compression.
Squamous cell carcinoma: central, smoking-linked, cavitation, hypercalcemia from PTHrP.
Small cell carcinoma: central, aggressive, smoking-linked, SIADH, ectopic ACTH, Lambert-Eaton; usually not surgical at presentation.
Adenocarcinoma: peripheral, common in non-smokers/women, may present as solitary pulmonary nodule.
Pancoast tumor: apical mass causing shoulder pain, Horner syndrome, lower brachial plexus symptoms.
Cord compression: vertebral metastasis compresses spinal cord; neurologic function depends on urgent steroid + MRI + decompression/radiotherapy pathway.
| STANDARD NAME | SYNONYMS | USED IN |
|---|---|---|
| SPN | Solitary pulmonary nodule | Single rounded lung opacity |
| SCLC | Small cell lung cancer | Central aggressive tumor |
| NSCLC | Non-small cell lung cancer | Adeno, squamous, large cell |
| Pancoast | Superior sulcus tumor | Shoulder pain/Horner/ulnar symptoms |
| MSCC | Metastatic spinal cord compression | Back pain + weakness + bladder symptoms |
| SQUAMOUS | SMALL CELL | ADENOCARCINOMA | PANCOAST | |
|---|---|---|---|---|
| Location | Central/cavitating | Central/hilar | Peripheral | Apical |
| Association | Smoking | Heavy smoking | Non-smoker possible | Smoking/NSCLC |
| Paraneoplastic | PTHrP hypercalcemia | SIADH, ACTH, Lambert-Eaton | Hypertrophic osteoarthropathy | Horner, brachial plexus |
| Trap | Mistaken TB abscess | Called surgical early | Ignored because non-smoker | Missed as shoulder disease |
Bottom row is the discriminator — the single feature that separates these conditions.
1. Suspected lung cancer CXR then CT chest; compare old imaging if SPN. Refer for tissue diagnosis and staging. Persistent hemoptysis, weight loss, or non-resolving consolidation needs malignancy workup. Smoking cessation and symptom control run alongside diagnostic pathway.
2. SPN risk logic Low-risk small stable nodule may be surveillance. Higher-risk nodule: CT characterization, PET-CT, biopsy or excision depending size/risk. Growth over time is malignant until proven otherwise. Calcified stable granuloma pattern is lower risk.
3. Paraneoplastic clues Hyponatremia/SIADH -> small cell. Hypercalcemia/PTHrP -> squamous. Proximal weakness improves with use -> Lambert-Eaton/small cell. Cushingoid features/hypokalemia -> ectopic ACTH/small cell.
4. Cord compression Give high-dose dexamethasone immediately if suspected. Urgent MRI whole spine/affected spine. Urgent oncology/neurosurgery/radiotherapy pathway. Do not wait for complete paralysis.
TRAP: HEMOPTYSIS IN SMOKER = TB ONLY TB is common, but older smoker with weight loss/non-resolving opacity needs cancer workup.
TRAP: SMALL CELL SURGERY Small cell is usually systemic at diagnosis; chemo/radiotherapy logic dominates.
TRAP: SIADH CAUSE MISSED Hyponatremia in smoker with hilar mass points to small cell lung cancer.
TRAP: BACK PAIN IN CANCER TREATED AS MUSCULOSKELETAL Back pain plus weakness or bladder symptoms is cord compression until proven otherwise.
| CORRECT PATTERN | TRAP PATTERN | CLUE THAT SEPARATES THEM |
|---|---|---|
| Smoker + central mass + SIADH -> small cell | Squamous | SIADH is small cell. |
| Central cavitating mass + hypercalcemia -> squamous | Adenocarcinoma | PTHrP hypercalcemia is squamous. |
| Known lung cancer + leg weakness + urinary retention -> cord compression | Routine analgesia | Neurologic bladder signs make it an emergency. |
| Apical tumor + Horner -> Pancoast | Cervical radiculopathy only | Shoulder/ulnar symptoms plus Horner localize to apex. |
| 01 Red flags Smoker, hemoptysis, weight loss, persistent cough, recurrent/non-resolving pneumonia. | 02 Image CXR then CT chest; SPN risk by size/growth/patient risk. | 03 Histology clue Central SIADH small cell; central hypercalcemia squamous; peripheral adenocarcinoma. | 04 Stage/tissue Biopsy and staging before definitive treatment. | 05 Emergency Cord compression -> steroid + MRI now. |
| TRIGGER | Smoker with hemoptysis/weight loss or known lung cancer with neurologic symptoms. |
| DISCRIMINATOR | Paraneoplastic syndrome identifies histology; neurologic/bladder symptoms identify cord compression. |
| TRAP | Treating SIADH as primary endocrine disease or missing MSCC. |
| ACTION | Work up cancer, match paraneoplastic clue, treat cord compression immediately. |
| FUTURE ALERT | In lung cancer MCQs, sodium/calcium/weakness often matters more than the chest mass. |
| HOW IT'S TESTED | exam banks test SIADH small cell, cord compression emergency, smoking red flags, SPN/cancer vs TB patterns. |
| THE DISGUISE | May appear as hyponatremia, back pain, shoulder pain, or non-resolving pneumonia. |
| DISCRIMINATION REWARDED | The key is linking systemic clue to lung cancer subtype or emergency metastasis. |
EXAM ESSENTIAL Back pain plus weakness/urinary retention in lung cancer is metastatic spinal cord compression: dexamethasone and urgent MRI, not routine outpatient follow-up.
| >3 cm Mass rather than nodule concept | 2 years stable Suggests benign SPN in many classic algorithms | SIADH Small cell clue |
| PTHrP Squamous hypercalcemia clue |
1. Smoker + hilar mass + hyponatremia: Answer: Small cell lung cancer with SIADH
2. Central cavitating tumor + hypercalcemia: Answer: Squamous cell carcinoma
3. Apical tumor + Horner syndrome: Answer: Pancoast tumor
4. Cancer + back pain + urinary retention: Answer: Metastatic spinal cord compression
| TAG | TIER | WHY IT MATTERS |
|---|---|---|
| QBank | exam evidence | Lung cancer SIADH and cord compression items. |
| Respiratory series | Production spine | Cancer/SPN red-flag topic. |
Bottom line — Lung cancer stems often test paraneoplastic syndromes or metastasis emergencies.
EXAM ESSENTIAL Exam essential: Cord compression is a steroid-plus-urgent-MRI emergency.
Vignette — A 28-year-old man has years of daily productive cough with large volumes of foul-smelling sputum, recurrent chest infections, coarse crackles, clubbing, and intermittent hemoptysis. HRCT shows dilated bronchi with signet-ring appearance. Recognition Pattern — Bronchiectasis questions test chronic productive cough, recurrent infections, hemoptysis, HRCT diagnosis, organism clues, and CF/primary ciliary dyskinesia associations.
Chronic daily purulent sputum + recurrent infections + coarse crackles/clubbing + HRCT dilated bronchi = bronchiectasis.
Bronchiectasis: irreversible bronchial dilation from chronic infection/inflammation and impaired mucociliary clearance.
Vicious cycle: infection damages airways -> impaired clearance -> more infection.
CF: CFTR dysfunction causes thick secretions, recurrent sinopulmonary infection, pancreatic insufficiency, infertility in males.
Pseudomonas colonization: marker of more severe disease and frequent exacerbations.
Hemoptysis: inflamed bronchial arteries can bleed; massive hemoptysis is an airway emergency.
| STANDARD NAME | SYNONYMS | USED IN |
|---|---|---|
| Bronchiectasis | Irreversible bronchial dilation | Daily purulent sputum |
| HRCT | High-resolution CT | Signet-ring/tram-track bronchi |
| CF | Cystic fibrosis | Thick secretions, pancreatic insufficiency |
| PCD | Primary ciliary dyskinesia/Kartagener | Sinusitis, bronchiectasis, infertility, situs inversus |
| Exacerbation | Increased sputum/cough/dyspnea | Often infectious |
| BRONCHIECTASIS | CHRONIC BRONCHITIS | TB | CF | |
|---|---|---|---|---|
| Sputum | Large-volume purulent/foul | Morning productive cough | Hemoptysis + constitutional | Thick recurrent infections |
| Clue | Recurrent infections, clubbing | Smoker, COPD | Night sweats/weight loss | Pancreatic insufficiency/infertility |
| Best test | HRCT | Spirometry | AFB/GeneXpert/CXR | Sweat chloride/CFTR |
| Trap | Called asthma | Called simple COPD | Missed as cancer only | Missed in adult presentation |
Bottom row is the discriminator — the single feature that separates these conditions.
1. Diagnosis HRCT is the key diagnostic test. Sputum culture during exacerbations and for chronic colonization. Look for cause: post-infectious, TB, ABPA, immunodeficiency, CF, PCD, aspiration. Assess severity by exacerbations, FEV1, colonization, hemoptysis.
2. Stable care Airway clearance physiotherapy. Vaccination and smoking avoidance. Treat underlying cause where found. Macrolide prophylaxis may be used in frequent exacerbations under specialist care.
3. Exacerbation Antibiotics guided by prior cultures/current sputum. Cover Pseudomonas if known colonization or severe disease. Increase airway clearance and bronchodilator if wheezy/obstructed. Hospitalize if hypoxic, septic, massive hemoptysis, or failing oral therapy.
4. CF-specific Sweat chloride/CFTR testing when suspected. Pancreatic enzyme replacement and nutrition support if pancreatic insufficiency. Airway clearance, targeted antibiotics, CF specialist care. Male infertility from congenital bilateral absence of vas deferens is classic.
TRAP: BRONCHIECTASIS DIAGNOSED BY CXR CXR can suggest but HRCT is the diagnostic test.
TRAP: CHRONIC SPUTUM EQUALS COPD Large-volume purulent sputum, recurrent infections, clubbing, and HRCT dilation point to bronchiectasis.
TRAP: HEMOPTYSIS IGNORED Massive hemoptysis is an airway emergency.
TRAP: CF ONLY IN CHILDREN Milder CF can present later with bronchiectasis, infertility, sinus disease, or pancreatitis.
| CORRECT PATTERN | TRAP PATTERN | CLUE THAT SEPARATES THEM |
|---|---|---|
| Daily purulent sputum + HRCT signet ring -> bronchiectasis | Asthma | Asthma is episodic wheeze, not chronic purulent sputum. |
| Bronchiectasis best test -> HRCT | Chest X-ray | CXR is not most accurate. |
| Sinusitis + situs inversus + infertility -> Kartagener/PCD | CF | Situs inversus points to ciliary dyskinesia. |
| Pancreatic insufficiency + recurrent lung infections -> CF | TB | Multisystem thick secretions are CF. |
| 01 Recognize Daily purulent sputum, recurrent infections, crackles, clubbing. | 02 Confirm HRCT. | 03 Culture Sputum organisms, especially Pseudomonas. | 04 Cause TB, ABPA, immune deficiency, CF/PCD, aspiration. | 05 Treat Airway clearance + culture-guided antibiotics. |
| TRIGGER | Chronic large-volume purulent sputum with recurrent infections. |
| DISCRIMINATOR | HRCT signet-ring bronchial dilation confirms bronchiectasis; pancreatic/sinus/infertility clues identify CF/PCD. |
| TRAP | Calling it asthma or COPD from cough alone. |
| ACTION | Confirm with HRCT, culture sputum, airway clearance, antibiotics by organism, evaluate cause. |
| FUTURE ALERT | Bronchiectasis MCQs reward sputum volume and recurrent infection pattern. |
| HOW IT'S TESTED | QBank patterns test bronchiectasis vs asthma/TB/pneumonia and chronic cough differentials. |
| THE DISGUISE | May appear as hemoptysis or recurrent pneumonia rather than named bronchiectasis. |
| DISCRIMINATION REWARDED | Daily purulent sputum plus HRCT is the separator. |
EXAM ESSENTIAL Massive hemoptysis in bronchiectasis is an airway emergency requiring urgent stabilization.
| HRCT Best diagnostic test | Pseudomonas Severe/chronic colonization clue | Sweat chloride CF diagnostic clue |
| Situs inversus Kartagener/PCD clue |
1. Best test for bronchiectasis: Answer: HRCT chest
2. Large-volume purulent sputum for years: Answer: Bronchiectasis
3. Bronchiectasis + sinusitis + situs inversus: Answer: Kartagener syndrome
4. Recurrent infections + pancreatic insufficiency: Answer: Cystic fibrosis
| TAG | TIER | WHY IT MATTERS |
|---|---|---|
| QBank | exam evidence | Bronchiectasis appears in differential options against asthma/TB/pneumonia. |
Bottom line — Bronchiectasis is a chronic infected-airway clearance disease; HRCT clinches it.
WHY IT MATTERS Future alert: Chronic sputum quantity matters: large-volume purulent sputum is bronchiectasis until proven otherwise.
Vignette — A 65-year-old woman has progressive exertional dyspnea, dry cough, bibasal fine end-inspiratory crackles, and clubbing. HRCT shows subpleural basal honeycombing. Another patient with mining exposure has upper-lobe nodules and progressive massive fibrosis. Recognition Pattern — ILD questions test restrictive lung disease, dry cough/fine crackles/clubbing, HRCT patterns, occupational exposure clues, and UIP/IPF vs pneumoconiosis.
Progressive dyspnea + dry cough + fine Velcro crackles + clubbing + restrictive PFT = ILD. Exposure history separates occupational lung disease.
ILD: inflammation/fibrosis thickens interstitium, reducing lung compliance and diffusion capacity.
Restrictive PFT: low FVC/TLC with normal or high FEV1/FVC.
IPF/UIP: subpleural basal fibrosis, honeycombing, fibroblastic foci, temporal heterogeneity.
Pneumoconiosis: inhaled mineral dust causes nodules/fibrosis; pattern depends on exposure.
Hypersensitivity pneumonitis: immune reaction to organic antigen; bird/farmer/humidifier exposure.
| STANDARD NAME | SYNONYMS | USED IN |
|---|---|---|
| ILD | Interstitial lung disease | Restrictive fibrotic lung disease |
| IPF/UIP | Idiopathic pulmonary fibrosis/usual interstitial pneumonia | Basal subpleural honeycombing |
| Asbestosis | Asbestos-related ILD | Lower-lobe fibrosis, pleural plaques |
| Silicosis | Silica exposure | Upper-lobe nodules, TB risk |
| Coal worker pneumoconiosis | Coal dust lung disease | Upper-lobe nodules/PMF |
| HP | Hypersensitivity pneumonitis | Bird/farmer exposure |
| ASBESTOS | SILICA | COAL | HYPERSENSITIVITY PNEUMONITIS | |
|---|---|---|---|---|
| Exposure | Shipyard, insulation, construction | Mining, sandblasting | Coal mining | Birds, moldy hay, humidifier |
| Pattern | Lower-lobe fibrosis + pleural plaques | Upper-lobe nodules/eggshell nodes | Upper-lobe nodules/PMF | Ground glass/centrilobular nodules |
| Cancer/TB link | Mesothelioma/bronchogenic cancer | TB risk | PMF | Not cancer classic |
| Trap | Miss pleural plaques | Called TB only | Called COPD | Miss antigen history |
Bottom row is the discriminator — the single feature that separates these conditions.
1. Diagnosis PFT: restrictive pattern and reduced DLCO. HRCT is central for pattern recognition. Ask exposure history: job, birds, molds, drugs, connective-tissue symptoms. Exclude infection, HF, COPD, malignancy when needed.
2. IPF/UIP Refer respiratory/ILD specialist. Antifibrotics may slow progression in IPF. Oxygen/pulmonary rehab/supportive care. Transplant evaluation in selected advanced cases.
3. Occupational disease Remove/avoid exposure. Notify occupational health/public health where required. Smoking cessation especially with asbestos exposure. Monitor for complications: TB in silicosis, malignancy in asbestos.
4. Hypersensitivity pneumonitis Identify and remove antigen. Steroids may be used for significant inflammatory disease. Chronic fibrotic HP behaves like progressive ILD.
TRAP: ILD IS OBSTRUCTIVE ILD is restrictive: low TLC/FVC, preserved or high FEV1/FVC.
TRAP: ASBESTOS AFFECTS UPPER LOBES Asbestosis classically lower-lobe fibrosis with pleural plaques.
TRAP: SILICA CANCER ONLY Silicosis is strongly linked with TB risk.
TRAP: IPF WITHOUT HRCT HRCT pattern is central; biopsy terms like fibroblastic foci/honeycombing point UIP.
| CORRECT PATTERN | TRAP PATTERN | CLUE THAT SEPARATES THEM |
|---|---|---|
| Basal subpleural honeycombing -> UIP/IPF | Sarcoidosis | Sarcoid often hilar nodes/upper-lobe pattern. |
| Pleural plaques + lower-lobe fibrosis -> asbestos | Silica | Silica is upper-lobe nodules/eggshell calcification. |
| Mining + upper-lobe nodules + TB risk -> silicosis | Asbestosis | Exposure and lobe pattern separate them. |
| Bird exposure + ILD symptoms -> hypersensitivity pneumonitis | IPF | Antigen exposure is the clue. |
| 01 Pattern Dry cough/dyspnea/fine crackles/clubbing. | 02 PFT Restrictive + low DLCO. | 03 HRCT UIP, nodules, plaques, ground glass. | 04 Exposure Asbestos, silica, coal, birds/mold, drugs. | 05 Treat Remove exposure, specialist care, antifibrotic/steroid/support by cause. |
| TRIGGER | Progressive dyspnea, dry cough, Velcro crackles, restrictive PFT. |
| DISCRIMINATOR | HRCT/exposure clue decides IPF vs occupational vs HP. |
| TRAP | Calling restriction COPD or missing exposure history. |
| ACTION | Identify pattern, get HRCT/PFT, remove exposure, refer/manage cause. |
| FUTURE ALERT | ILD questions are exposure-history questions wearing a dyspnea costume. |
| HOW IT'S TESTED | QBank patterns include ILD, occupational asthma/disease, UIP biopsy clue, and restrictive physiology. |
| THE DISGUISE | May appear as pathology biopsy, occupational history, or chronic dyspnea. |
| DISCRIMINATION REWARDED | Restrictive PFT plus exposure/HRCT pattern is the separator. |
EXAM ESSENTIAL Do not miss asbestos/silica exposure history; it changes counseling, surveillance, and TB/cancer risk thinking.
| FEV1/FVC normal/high Restrictive pattern clue | Low DLCO Interstitial diffusion impairment | Honeycombing UIP/IPF HRCT clue |
| Pleural plaques Asbestos exposure clue |
1. Restrictive PFT pattern: Answer: Low TLC/FVC, normal or high FEV1/FVC
2. Basal honeycombing: Answer: UIP/IPF
3. Pleural plaques: Answer: Asbestos
4. Silicosis complication: Answer: Increased TB risk
| TAG | TIER | WHY IT MATTERS |
|---|---|---|
| QBank | exam evidence | ILD, occupational asthma/disease, UIP clue items. |
Bottom line — ILD = restrictive dry cough dyspnea; occupational ILD = exposure clue plus HRCT pattern.
EXAM ESSENTIAL Exam essential: Restrictive lung disease has preserved/high FEV1/FVC, not low FEV1/FVC.
Vignette — A 28-year-old man presents with hemoptysis and dyspnea. Urinalysis shows hematuria and RBC casts. Anti-GBM antibody is positive. Another patient has chronic sinusitis, nasal obstruction, hemoptysis, hematuria, and c-ANCA positivity. Recognition Pattern — Pulmonary-renal questions test hemoptysis plus nephritic urine, then separate Goodpasture from GPA/vasculitis/SLE using antibody, ENT signs, and systemic clues.
Hemoptysis + hematuria/RBC casts = pulmonary-renal syndrome. Anti-GBM = Goodpasture. ENT disease + c-ANCA/PR3 = GPA.
Diffuse alveolar hemorrhage: pulmonary capillary injury causes hemoptysis, dyspnea, anemia, and bilateral infiltrates/ground glass.
Glomerulonephritis: immune injury causes hematuria, RBC casts, proteinuria, and rising creatinine.
Goodpasture: anti-GBM antibodies against type IV collagen in lung and kidney basement membranes.
GPA: necrotizing granulomatous small-vessel vasculitis affecting ENT, lungs, kidneys; classically c-ANCA/PR3.
SLE pulmonary-renal: immune complex disease with systemic lupus clues, low complement, anti-dsDNA.
| STANDARD NAME | SYNONYMS | USED IN |
|---|---|---|
| Goodpasture | Anti-GBM disease | Hemoptysis + nephritic urine |
| GPA | Granulomatosis with polyangiitis/Wegener | ENT + lung + kidney |
| MPA | Microscopic polyangiitis | Lung-kidney vasculitis without granulomas |
| DAH | Diffuse alveolar hemorrhage | Hemoptysis/anemia/infiltrates |
| RBC casts | Nephritic sediment | Glomerulonephritis clue |
| GOODPASTURE | GPA | SLE | MPA | |
|---|---|---|---|---|
| Antibody | Anti-GBM | c-ANCA/PR3 | ANA, anti-dsDNA, low C3/C4 | p-ANCA/MPO |
| ENT clues | Usually absent | Sinusitis, nasal crusting, otitis | Oral ulcers possible | Usually absent |
| Lung | Alveolar hemorrhage | Nodules/cavitations/hemorrhage | Pleuritis/DAH possible | DAH |
| Kidney | Rapid GN | Rapid GN | Lupus nephritis | Rapid GN |
| Trap | Called PE/TB only | ENT clue ignored | No systemic lupus link | Confused with GPA |
Bottom row is the discriminator — the single feature that separates these conditions.
1. Recognize emergency Hemoptysis plus nephritic urine is not simple bronchitis or pneumonia. Check CBC, creatinine, urinalysis, CXR/CT, oxygenation. Assess severity: hypoxia, anemia, rising creatinine, pulmonary hemorrhage.
2. Diagnostic tests Anti-GBM antibody for Goodpasture. ANCA with PR3/MPO for GPA/MPA. ANA, anti-dsDNA, complements for SLE. Renal biopsy often confirms rapidly progressive GN pattern when needed.
3. Initial treatment logic High-dose corticosteroids for severe immune pulmonary-renal disease. Goodpasture: plasma exchange plus immunosuppression in classic severe disease. ANCA vasculitis: steroids plus rituximab or cyclophosphamide pathway. Support oxygen/ventilation, renal support/dialysis if needed.
4. Do not miss mimics PE causes pleuritic pain/dyspnea but not RBC casts. TB causes hemoptysis/weight loss but nephritic urine pushes pulmonary-renal syndrome. Pneumonia causes infiltrate/fever but anti-GBM/ANCA/urine sediment changes answer.
TRAP: HEMOPTYSIS MEANS TB ONLY Hemoptysis plus hematuria/RBC casts is pulmonary-renal syndrome until proven otherwise.
TRAP: GOODPASTURE VS GPA Goodpasture = anti-GBM and no ENT granulomatous story; GPA = ENT disease and c-ANCA/PR3.
TRAP: PE CHOSEN DESPITE RBC CASTS RBC casts are glomerulonephritis, not PE.
TRAP: DELAY IMMUNOSUPPRESSION IN DAH/RPGN Pulmonary hemorrhage plus rapidly progressive GN is organ-threatening.
| CORRECT PATTERN | TRAP PATTERN | CLUE THAT SEPARATES THEM |
|---|---|---|
| Anti-GBM + hemoptysis + RBC casts -> Goodpasture | GPA | Anti-GBM is decisive. |
| Sinusitis/nasal obstruction + c-ANCA + lung/kidney -> GPA | Goodpasture | ENT granulomatous disease points GPA. |
| Hemoptysis + hematuria -> pulmonary-renal syndrome | Simple pulmonary embolism | Urine sediment is the separator. |
| Low complement + anti-dsDNA -> SLE nephritis with lung involvement | ANCA vasculitis | Lupus serology and complement pattern separate it. |
| 01 Recognize Hemoptysis plus nephritic urine/RBC casts. | 02 Stabilize Oxygen, anemia, renal function, ICU if DAH severe. | 03 Antibodies Anti-GBM, ANCA PR3/MPO, ANA/dsDNA/complement. | 04 Classify Goodpasture vs GPA/MPA vs SLE. | 05 Treat Steroids, plasma exchange/rituximab/cyclophosphamide by cause. |
| TRIGGER | Hemoptysis with hematuria and RBC casts. |
| DISCRIMINATOR | Anti-GBM vs c-ANCA/ENT vs lupus serology. |
| TRAP | Picking TB/PE from hemoptysis alone and ignoring urine. |
| ACTION | Recognize pulmonary-renal syndrome, test antibodies, start urgent immunosuppressive pathway when severe. |
| FUTURE ALERT | In any hemoptysis stem, always scan urine clues. |
| HOW IT'S TESTED | recalled/QBank items test Goodpasture as hemoptysis plus hematuria/RBC casts and anti-GBM, with GPA as the ENT/c-ANCA confusion pair. |
| THE DISGUISE | May appear as respiratory, renal, rheumatology, or ENT complaint. |
| DISCRIMINATION REWARDED | Urine sediment and antibody are the answer. |
EXAM ESSENTIAL Diffuse alveolar hemorrhage plus rapidly progressive GN can kill lungs and kidneys; do not treat as routine pneumonia/TB.
| Anti-GBM Goodpasture antibody | c-ANCA/PR3 GPA clue | RBC casts Glomerulonephritis clue |
| Low C3/C4 SLE immune-complex clue |
1. Hemoptysis + hematuria + anti-GBM: Answer: Goodpasture syndrome
2. Sinusitis + hemoptysis + hematuria + c-ANCA: Answer: GPA
3. RBC casts indicate: Answer: Glomerulonephritis
4. Pulmonary-renal syndrome first pattern: Answer: Diffuse alveolar hemorrhage + GN
| TAG | TIER | WHY IT MATTERS |
|---|---|---|
| Recalled/QBank | Tier 1 evidence | Goodpasture hemoptysis + hematuria recalled repeatedly. |
| Respiratory/Renal production map | Production spine | High-yield overlap topic. |
Bottom line — Hemoptysis plus urine blood/RBC casts is pulmonary-renal, not just pulmonary.
EXAM ESSENTIAL Exam essential: Anti-GBM = Goodpasture; c-ANCA + ENT = GPA.
Purpose: Final rapid-review pack for the 12-topic Pulmonology MedCORE series.
Use: Read these tables after topic review, before the exam respiratory blocks, and after every respiratory error-log review.
Rule: In respiratory MCQs, the answer usually turns on one discriminator: percussion note, oxygen response, ABG pH/CO2, exposure clue, antibody, or hemodynamic status.
| FEATURE | ASTHMA | COPD |
|---|---|---|
| Patient | Young, atopy, triggers, nocturnal symptoms | Older smoker/biomass exposure |
| Pattern | Episodic and variable | Persistent and progressive |
| Spirometry | Reversible obstruction | Post-BD FEV1/FVC <0.70 |
| Acute danger | Silent chest, exhaustion, rising PaCO2 | Acidotic hypercapnia |
| Acute support | SABA, steroid, ipratropium, Mg/ICU if severe | Controlled O2, SABA/SAMA, steroid, NIV if acidotic |
| Chronic trap | LABA alone or SABA-only | High-flow O2 to 100%, chronic oral steroids |
| ORGANISM | CLASSIC CLUE | TRAP |
|---|---|---|
| Strep pneumoniae | Most common CAP, rusty sputum, lobar consolidation | Do not choose Mycoplasma as #1 CAP |
| H. influenzae | COPD/children, chocolate agar, needs X+V | No growth on blood agar clue |
| Klebsiella | Alcoholic/diabetic, currant-jelly sputum, bulging fissure | Can mimic TB/cancer cavity |
| Mycoplasma | Young adult, dry cough, cold agglutinins | Atypical, not classic #1 overall |
| Legionella | Water/AC exposure, diarrhea, hyponatremia | Urine antigen clue |
| Staph aureus | Post-influenza severe/necrotizing pneumonia | MRSA coverage only when risk clue exists |
| ITEM | RULE | TRAP |
|---|---|---|
| Active pulmonary TB | Cough, weight loss, night sweats, apical cavity, AFB+ | Do not treat with 2 drugs initially |
| Intensive phase | RHZE/RIPE for 2 months | Missing pyrazinamide risks failure/resistance |
| Continuation | INH + rifampicin classically 4 months | Only after intensive phase in drug-susceptible disease |
| INH | Peripheral neuropathy; give pyridoxine | Confused with ethambutol |
| Pyrazinamide | Hyperuricemia, gout-like joint pain | Confused with INH |
| Ethambutol | Optic neuritis, red-green color blindness | Not the joint-pain drug |
| Rifampicin | Orange secretions, hepatitis, drug interactions | Warn patient before panic |
| Immunology/BCG | TB/PPD = Type IV; BCG best prevents severe childhood TB | BCG does not reliably prevent adult pulmonary TB |
| DISCRIMINATOR | MEANING | TRAP |
|---|---|---|
| Stony dullness | Pleural effusion | Pneumothorax is hyperresonant |
| Bilateral CHF picture | Likely transudate; treat HF if typical | Unilateral/atypical still needs tap |
| Protein ratio >0.5 | Exudate by Light criteria | Any one criterion positive is enough |
| LDH ratio >0.6 | Exudate by Light criteria | Do not require all criteria |
| Pleural LDH >2/3 ULN | Exudate by Light criteria | Use OR logic |
| Pus or low pH/glucose | Empyema/complicated parapneumonic effusion | Needs drainage plus antibiotics |
| Weight loss/recurrent unilateral | Malignancy/TB workup | Do not assume CHF |
| PATTERN | IMMEDIATE STEP | TRAP |
|---|---|---|
| Tension: hypotension, JVP, tracheal shift, absent sounds | Needle decompression immediately, then chest tube | Do not wait for CXR |
| Open/sucking chest wound | Three-sided/vented dressing, then chest tube | Do not fully seal without venting |
| Stable small primary spontaneous | Observation/oxygen or aspiration by size/symptoms | Do not overtreat every tiny stable case |
| Secondary spontaneous | Lower threshold for admission/chest tube | COPD/TB patients have poor reserve |
| Traumatic/ventilated patient | Chest tube if significant | Positive pressure can worsen tension |
| Effusion vs pneumothorax | Effusion dull; pneumothorax hyperresonant | Both reduce breath sounds |
| STEP | QUESTION | HIGH-YIELD RULE |
|---|---|---|
| 1. pH | Acidemia or alkalemia? | Start here, not PaO2 |
| 2. PaCO2 | Does CO2 explain pH? | High CO2 = respiratory acidosis; low CO2 = respiratory alkalosis |
| 3. HCO3 | Does bicarbonate explain pH? | Low HCO3 = metabolic acidosis; high HCO3 = metabolic alkalosis |
| 4. Compensation | Is other system moving correctly? | Compensation never overshoots |
| 5. Oxygenation | Type 1 or Type 2 respiratory failure? | Type 1: low O2 normal/low CO2; Type 2: low O2 high CO2 |
| 6. Support | What does patient need? | COPD pH low + CO2 high = NIV/BiPAP if suitable |
| 7. Shunt | Does 100% O2 fail? | Poor oxygen response = shunt, not simple V/Q mismatch |
| PATTERN | MOST LIKELY | DISCRIMINATOR |
|---|---|---|
| Chronic cough, weight loss, night sweats, apical cavity | TB | AFB+, constitutional symptoms |
| Older smoker, weight loss, persistent cough/non-resolving opacity | Lung cancer | Smoking red flags, mass, paraneoplastic clue |
| Daily purulent sputum, recurrent infections, clubbing | Bronchiectasis | HRCT dilated bronchi |
| Hemoptysis + hematuria/RBC casts | Pulmonary-renal syndrome | Anti-GBM or ANCA decides |
| Sudden pleuritic pain/dyspnea after flight/OCP | Pulmonary embolism | Risk factor + CTPA/D-dimer logic |
| Fever, cough, consolidation | Pneumonia | Infiltrate + organism clue |
| Massive hemoptysis | Airway emergency | Stabilize airway before elegant diagnosis |
| FATAL MISS | CORRECT REFLEX | FUTURE ALERT |
|---|---|---|
| Silent chest in asthma | Treat as life-threatening; ICU/intubation prep if failing | Less wheeze can mean less airflow |
| COPD acidotic hypercapnia | Controlled O2 + NIV/BiPAP if suitable | pH decides support |
| Tension pneumothorax | Needle decompression before imaging | Unstable chest = action first |
| Massive PE with hypotension | Thrombolysis if eligible | BP is the PE pivot |
| Empyema | Drain plus antibiotics | Infected pleural space needs source control |
| Active TB undertreated | Start four-drug intensive phase when indicated | Active TB is not a two-drug start |
| Cord compression from lung cancer | Dexamethasone + urgent MRI/pathway | Back pain + bladder/weakness is emergency |
| Pulmonary-renal syndrome | Recognize DAH + GN; urgent antibodies/immunosuppression pathway | Hemoptysis + RBC casts is not routine pneumonia |
Black version later: Generate black/print variants after content review if needed.
MCQ hook: Use these tables as the source skeleton for a 50-question Pulmonology review block.
Error-log hook: Any repeated respiratory miss should be mapped to one table row and one future alert.
EXAM ESSENTIAL Pulmonology final pattern: percussion note, ABG pH/CO2, oxygen response, hemodynamic status, antibody, and exposure history are the high-yield discriminators.
Correct: B) Silent chest on auscultation
Concept: Acute asthma severity — life-threatening signs Interpretation
Why B: The source's severity ladder moves from acute severe (short sentences, RR/HR rise, accessory muscles) to life-threatening once silent chest, confusion, cyanosis, bradycardia, exhaustion, or a rising PaCO2 appear. Silent chest means airflow is critically low.
Discriminator: The vignette stops one step below the life-threatening tier; the examiner wants the single feature that pushes the patient into impending-arrest territory.
| A) SpO2 of 91% on room air | Hypoxia is concerning, but severe asthma is still graded by speech, RR, HR, exhaustion, silent chest, and PaCO2 trend — SpO2 91% alone does not make it life-threatening. |
| C) HR of 110/min | Tachycardia is expected in acute severe asthma; it is not the life-threatening criterion. |
| D) RR of 28/min | Tachypnea is a severity feature, but the life-threatening tier is marked by silent chest, confusion, cyanosis, bradycardia, exhaustion, or rising PaCO2. |
| E) PEF below 50% predicted | PEF is useful but the stem's life-threatening descriptors (silent chest, exhaustion, confusion, rising PaCO2) override a single PEF value. |
Trap: Less wheeze looks like improvement — the source names silent chest as the classic false-reassurance trap in this exact ladder.
Future alert: If the patient is quiet, confused, exhausted, cyanosed, bradycardic, or PaCO2 is normal/rising, treat as life-threatening, not as resolving.
Correct: C) LABA must be paired with an inhaled corticosteroid (ICS) in asthma
Concept: LABA monotherapy in asthma — the mortality trap Analysis
Why C: Salmeterol/formoterol alone in asthma is unsafe: LABA without ICS is the named mortality trap, so any stem pairing LABA monotherapy with asthma is testing this exact error.
Discriminator: The stem gives LABA alone as the maintenance regimen — the single unsafe chronic combination in the source's EXAM TRAPS.
| A) Add a leukotriene receptor antagonist before any ICS | The source's controller logic is ICS-containing therapy; leukotriene modifiers are not the fix for LABA monotherapy. |
| B) Continue salmeterol alone since symptoms are controlled | LABA without ICS is unsafe in asthma — the source names it explicitly as the mortality trap. |
| D) Switch to salbutamol alone as maintenance | SABA-only chronic treatment is the other named error; controllers prevent risk and reduce exacerbations. |
| E) Keep LABA and add theophylline | Theophylline is low-yield in asthma escalation and carries a narrow therapeutic window. |
Trap: The trap is 'symptoms are controlled, so do nothing' — the source warns the exam swims in this direction whenever salmeterol/formoterol appears alone.
Future alert: In asthma, LABA never travels alone: pair with ICS or the option is wrong.
Correct: D) It is a danger sign suggesting fatigue and impending ventilatory failure
Concept: PaCO2 trend in severe asthma Interpretation
Why D: Early severe asthma hyperventilates and drives PaCO2 down; a normal or rising PaCO2 therefore means ventilatory failure is developing, not that the gas is fine.
Discriminator: The 2-hour timing plus normal PaCO2 is the loaded clue — the source pairs 'normal/rising PaCO2' with fatigue and impending arrest.
| A) It confirms improvement because the gas is now normal | Early severe asthma causes hypocapnia from hyperventilation, so a normal PaCO2 means CO2 is climbing, not normalizing in the reassuring sense. |
| B) It indicates the attack is mild | Severity here is judged alongside speech, RR, work of breathing, and SpO2 — a normal PaCO2 mid-attack is not a mild-attack marker. |
| C) It shows she is ready for discharge | Normal or rising PaCO2 in severe asthma is the opposite of a discharge signal. |
| E) It means oxygen therapy can be stopped | Oxygen decisions follow SpO2 targets, not the PaCO2 value in isolation. |
Trap: The number looks reassuringly normal; the trick is that 'normal' is the wrong direction for a hyperventilating asthmatic.
Future alert: Normal or rising PaCO2 in severe asthma = impending ventilatory failure, not reassurance.
Correct: E) Start an ICS-containing controller
Concept: Chronic asthma control — controller escalation Interpretation
Why E: Recurrent day and night symptoms plus regular reliever use mean poor control; the source's chronic answer is an ICS-containing controller, never SABA-only or LABA-only maintenance.
Discriminator: Daytime symptoms, nocturnal waking, and frequent blue-inhaler use are the three control signals the source lists for stepping up.
| A) Continue SABA-only therapy and recheck in 6 months | Frequent reliever use signals poor control and future exacerbation risk; SABA alone does not treat inflammation. |
| B) Add a LABA without ICS | LABA monotherapy is the named mortality trap in asthma. |
| C) Schedule spirometry and start nothing until it returns | The escalating symptoms already justify controller initiation; treatment need not wait on spirometry. |
| D) Refer for allergy testing before any treatment | Allergen/trigger review is part of the workup, not a prerequisite that delays controller therapy. |
Trap: The examiner dresses the 'no controller yet' patient as a mild case; reliever frequency is the tell.
Future alert: Frequent salbutamol use = poor control: add or step up ICS-containing therapy, not SABA.
Correct: A) NIV/BiPAP with controlled oxygen
Concept: AECOPD with acidotic hypercapnia — NIV decision Analysis
Why A: pH 7.28 with PaCO2 72 is acute-on-chronic hypercapnic respiratory failure; NIV/BiPAP is first-line if the patient is conscious, cooperative, and protects his airway, with ABG recheck after starting.
Discriminator: Drowsy but rousable + pH <7.35 + high PaCO2 is the exact NIV trigger pair; the ABG converts a COPD question into a ventilatory-support question.
| B) High-flow oxygen to normalize SpO2 | Indiscriminate high-flow oxygen can worsen CO2 retention; acidotic hypercapnia is a ventilatory-support question. |
| C) Immediate intubation and mechanical ventilation | NIV/BiPAP is first-line in acidotic hypercapnic failure when the patient is conscious, cooperative, and can protect the airway. |
| D) Oxygen alone with repeat ABG in 2 hours | Low pH plus high PaCO2 is ventilatory failure; oxygen alone while CO2 rises is the fatal miss named in the source. |
| E) IV aminophylline infusion | Theophylline is low-yield with a narrow therapeutic window and is not the first step for acidotic hypercapnia. |
Trap: The CO2-retaining COPD patient tempts 'give more oxygen'; the source flags high-flow oxygen and oxygen-alone as the fatal misses.
Future alert: COPD + low pH + high PaCO2 = NIV if suitable; ABG decides support, not symptom severity.
Correct: B) 88-92%
Concept: Oxygen target in CO2-retaining COPD Recall
Why B: COPD patients at risk of CO2 retention are managed with controlled oxygen targeting 88-92%, not indiscriminate high-flow oxygen.
Discriminator: Prior hypercapnic exacerbations mark him as a CO2 retainer — the stem plants the exact risk that selects the 88-92% target.
| A) 94-98% | That range suits patients without CO2-retention risk; this man's history pushes the target down. |
| C) 100% saturation | Forcing SpO2 to 100% with excessive oxygen can worsen CO2 retention in susceptible COPD patients. |
| D) Greater than 90% with any flow rate | The flow is titrated to the target range; uncontrolled high flow defeats the purpose of controlled oxygen. |
| E) Greater than 96% | Supra-normal targets ignore the Haldane/V-Q effects the source warns about in CO2 retainers. |
Trap: The trap is the reflexive 'normal-saturation' oxygen target; this population gets a lower range by design.
Future alert: In CO2-retaining COPD, oxygen target 88-92%, titrated, never 'give 100%'.
Correct: C) PaO2 ≤55 mmHg or SaO2 ≤88% at rest
Concept: LTOT — who actually qualifies Recall
Why C: LTOT is for chronic severe resting hypoxemia: PaO2 ≤55 mmHg or SaO2 ≤88%, or PaO2 56-59 with cor pulmonale/polycythemia — never breathlessness alone.
Discriminator: Exertional dyspnea without qualifying rest hypoxemia is the distractor profile the source explicitly disqualifies.
| A) Dyspnea on exertion with SpO2 90% | LTOT is for chronic severe resting hypoxemia, not breathlessness alone — dyspnea does not qualify. |
| B) PaO2 56-59 mmHg without complications | The 56-59 range qualifies only with cor pulmonale or polycythemia present. |
| D) Nocturnal desaturations to 85% | Intermittent sleep desaturation is not the classic resting-LTOT threshold named in the source. |
| E) Any SpO2 below 92% during an exacerbation | LTOT is a stable-state chronic criterion, not an acute-exacerbation oxygen decision. |
Trap: The source's trap is 'home oxygen for breathlessness alone' — symptoms do not override the numbers.
Future alert: LTOT requires chronic resting hypoxemia criteria; dyspnea alone never qualifies.
Correct: D) Alpha-1 antitrypsin deficiency
Concept: Young COPD — alpha-1 antitrypsin deficiency Interpretation
Why D: Young patient, minimal smoking, basilar panacinar emphysema, and liver disease is the classic alpha-1 antitrypsin deficiency cluster, and it must be triggered by this exact story.
Discriminator: Age <45, minimal smoking, basilar distribution, and liver involvement are the four source clues; the stem plants all of them.
| A) Smoking-related COPD | His age and minimal smoking exposure argue against ordinary smoking COPD. |
| B) Chronic asthma with fixed obstruction | Asthma does not produce basilar panacinar emphysema with liver enzyme elevation. |
| C) Alpha-1 antitrypsin is irrelevant to emphysema | A1AT deficiency is exactly the young non-smoker emphysema phenotype the source flags. |
| E) Bronchiectasis from recurrent infection | Basilar emphysema plus liver disease is an A1AT pattern, not bronchiectasis. |
Trap: The examiner hides a genetic cause behind a familiar 'emphysema' label; the young non-smoker profile unmaskes it.
Future alert: Young non-smoker with basilar emphysema or liver disease → alpha-1 antitrypsin deficiency.
Correct: E) Streptococcus pneumoniae
Concept: Most common CAP organism Recall
Why E: The source states Strep pneumoniae is the classic most common CAP answer, with rusty sputum and lobar consolidation as its signature clues.
Discriminator: Rusty sputum + lobar consolidation in a community patient is the exact organism-clue pairing from the source's table.
| A) Mycoplasma pneumoniae | Atypical organisms are common but not the classic #1 CAP answer; pneumonia with rusty sputum and lobar consolidation points to Strep pneumoniae. |
| B) Haemophilus influenzae | H. influenzae is the COPD/children organism and the chocolate-agar clue, not the classic #1 CAP cause. |
| C) Klebsiella pneumoniae | Klebsiella is the alcoholic/diabetic currant-jelly organism, not the #1 answer. |
| D) Staphylococcus aureus | Post-influenza necrotizing pneumonia is the Staph aureus story, not the classic most common CAP. |
Trap: Mycoplasma is the camouflage — the source warns it is 'common but not the classic #1 answer'.
Future alert: Rusty sputum + lobar consolidation = Strep pneumoniae; Mycoplasma is the trap, not the answer.
Correct: A) Haemophilus influenzae
Concept: Chocolate agar — H. influenzae Interpretation
Why A: H. influenzae requires the X and V factors supplied by chocolate agar, so growth on chocolate agar only is the classic culture clue.
Discriminator: COPD background + chocolate-agar-only growth is the exact two-clue pair from the source's organism table.
| B) Streptococcus pneumoniae | Strep pneumoniae grows on blood agar; the chocolate-agar-only pattern is not its signature. |
| C) Klebsiella pneumoniae | Klebsiella is the lactose-fermenting currant-jelly organism. |
| D) Legionella pneumophila | Legionella is the water/AC exposure organism detected by urine antigen. |
| E) Mycoplasma pneumoniae | Mycoplasma is an atypical with cold agglutinins, not a chocolate-agar-dependent coccobacillus. |
Trap: Blood agar gives no growth and tempts 'no pathogen found'; the chocolate medium is the discriminator.
Future alert: Tiny colonies on chocolate agar only = H. influenzae (needs X+V factors).
Correct: B) Intrapulmonary shunt through non-ventilated consolidated lung
Concept: Refractory hypoxemia — shunt physiology Analysis
Why B: Perfusion continues through non-ventilated consolidated lung, so oxygen cannot correct the hypoxemia — the source pairs 'PaO2 barely improves with 100% O2' with intrapulmonary shunt.
Discriminator: Failure to correct on 100% oxygen is the discriminator that separates shunt from V/Q mismatch in the source.
| A) Simple V/Q mismatch | V/Q mismatch improves with oxygen; a shunt barely responds, so near-zero correction points away from simple mismatch. |
| C) Diffusion defect alone | Diffusion limitation would improve substantially with high FiO2; refractory hypoxemia at 100% oxygen is the shunt signature. |
| D) Right-to-left cardiac shunt | No congenital heart clue is given; the consolidated pneumonia is the source's shunt mechanism. |
| E) Hypoventilation with CO2 retention | His PaCO2 is not stated as elevated; the oxygen-nonresponsive pattern is the story. |
Trap: V/Q mismatch is the reflex answer; the source calls out the shunt-versus-mismatch swap as a named trap.
Future alert: PaO2 barely rising on 100% O2 = shunt: escalate respiratory support, not 'more oxygen'.
Correct: C) Treat as hospital-acquired pneumonia with antipseudomonal and MRSA risk-based coverage
Concept: HAP timing and organism logic Interpretation
Why C: Onset at least 48 hours after admission defines HAP; the source shifts coverage toward gram-negatives and MRSA according to risk, with local antibiogram guidance.
Discriminator: The 72-hour post-admission timing is the single loaded number — the source defines HAP by the ≥48-hour threshold.
| A) Treat with the same outpatient CAP regimen | Pneumonia starting ≥48 hours after admission is HAP; ordinary outpatient CAP logic is the named trap. |
| B) Wait for blood cultures before starting antibiotics | Empiric therapy begins promptly; cultures refine rather than block treatment. |
| D) Add vancomycin automatically to all regimens | MRSA coverage is risk-based (MRSA risk or high local prevalence), not automatic for everyone. |
| E) Change to a macrolide alone | HAP requires broader gram-negative/MRSA-minded empiric coverage, not macrolide monotherapy. |
Trap: The trap is treating HAP like outpatient CAP; the timing moves the entire antibiotic logic.
Future alert: New infiltrate ≥48 hours after admission = HAP: antipseudomonal/MRSA-risk empiric logic, not outpatient CAP.
Correct: D) Rifampicin + isoniazid + pyrazinamide + ethambutol (RHZE/RIPE) for 2 months
Concept: Active pulmonary TB — intensive phase regimen Recall
Why D: Active pulmonary TB starts with RHZE/RIPE — four drugs for 2 months — then continuation with isoniazid + rifampicin for 4 months in drug-susceptible disease.
Discriminator: Apical cavitary lesion with AFB positivity is the classic reactivation cluster; the drug count is the tested rule.
| A) Isoniazid + rifampicin only | Active TB is not a two-drug disease at the start; two drugs risk failure and resistance. |
| B) Isoniazid + rifampicin + ethambutol for 6 months | The intensive phase classically includes pyrazinamide; omitting it risks failure/resistance. |
| C) Pyrazinamide + ethambutol for 2 months | Pyrazinamide and ethambutol without the two core sterilizing drugs is not an intensive-phase regimen. |
| E) Rifampicin + isoniazid + pyrazinamide alone | Active TB begins with four drugs; ethambutol is part of the classic intensive phase. |
Trap: The trap is the two-drug start; the source names 'active TB is not a two-drug disease at the start' as a fatal miss.
Future alert: Active TB begins with four drugs; pyrazinamide is not the drug you drop.
Correct: E) Pyrazinamide
Concept: ATT joint pain — pyrazinamide toxicity Interpretation
Why E: Pyrazinamide causes hyperuricemia and gout-like joint pain; the source matches this symptom explicitly to pyrazinamide.
Discriminator: Joint pain at 3 weeks on ATT is the exact symptom-to-drug stem; the serum urate elevation seals it.
| A) Isoniazid | INH causes peripheral neuropathy (prevented with pyridoxine), not hyperuricemia. |
| B) Rifampicin | Rifampicin causes orange secretions, hepatitis, and drug interactions — not gout-like joint pain. |
| C) Ethambutol | Ethambutol causes optic neuritis and red-green color blindness. |
| D) Streptomycin | Aminoglycoside toxicity is ototoxicity/nephrotoxicity, not hyperuricemic joint pain. |
Trap: INH is the reflex 'neuropathy' answer — the source warns pyrYZINAMIDE, not INH, owns the joints.
Future alert: Joint pain/hyperuricemia on ATT = pyrazinamide; neuropathy = INH; vision = ethambutol.
Correct: A) Add pyridoxine (vitamin B6) and attribute the neuropathy to isoniazid
Concept: ATT peripheral neuropathy — INH and pyridoxine Interpretation
Why A: INH causes peripheral neuropathy, and pyridoxine is given with INH to reduce neuropathy risk — the source matches burning feet to INH explicitly.
Discriminator: Burning/tingling feet at 2 months on ATT is the INH-neuropathy stem from the source's toxicity table.
| B) Switch ethambutol to an alternative | Ethambutol causes optic neuritis, not peripheral neuropathy. |
| C) Stop rifampicin for suspected hepatitis | Rifampicin hepatitis presents with jaundice and raised transaminases, not burning feet. |
| D) Reassure that this will self-resolve untreated | INH neuropathy is prevented and treated with pyridoxine; leaving it untreated risks progression. |
| E) Switch isoniazid to an alternative anti-TB agent | INH is a first-line core drug of the intensive phase; neuropathy is managed by adding pyridoxine, not by dropping isoniazid. |
Trap: Ethambutol (vision) and rifampicin (orange/jaundice) are the camouflage; the feet belong to INH.
Future alert: Burning feet on ATT = INH neuropathy: give pyridoxine.
Correct: B) Type IV (delayed cell-mediated hypersensitivity)
Concept: TB hypersensitivity type Recall
Why B: TB granulomas and the Mantoux/PPD response are Type IV delayed cell-mediated hypersensitivity, as the source states.
Discriminator: The stem pairs TB immunity with the PPD test — the same pair the source uses to anchor the Type IV answer.
| A) Type I (IgE-mediated) | Type I is immediate anaphylaxis/atopy, not the granuloma/PPD mechanism. |
| C) Type II (antibody-mediated cytotoxic) | Type II involves antibodies against cell surfaces, not TB granulomas. |
| D) Type III (immune complex) | Type III is immune-complex disease; the source explicitly rejects it for TB granulomas and PPD. |
| E) No immune mechanism — direct mycobacterial toxin damage | The granuloma and positive tuberculin test are adaptive cell-mediated (Type IV) responses, not direct toxin injury. |
Trap: Type III is the planted error; the source names the Type III-versus-Type IV swap as an exam trap.
Future alert: TB granuloma and PPD = Type IV delayed hypersensitivity, never Type III.
Correct: C) Pleural effusion
Concept: Effusion vs pneumothorax — percussion Interpretation
Why C: Stony dull percussion plus reduced breath sounds and reduced fremitus with a meniscus-oriented dyspnea story is the effusion signature; pneumothorax is hyperresonant.
Discriminator: Reduced breath sounds are shared by effusion and pneumothorax; the stony-dull note is the single discriminator the stem plants.
| A) Pneumothorax | Pneumothorax gives hyperresonance, not stony dullness; both can reduce breath sounds, so the note separates them. |
| B) Pulmonary embolism with infarction | PE does not classically produce stony dullness with reduced fremitus at one base. |
| D) Consolidation | Consolidation increases tactile fremitus and gives bronchial breath sounds, not reduced fremitus with dullness. |
| E) COPD with hyperinflation | Hyperinflation gives hyperresonance, not a stony-dull base with reduced fremitus. |
Trap: The examiner shares the two shared signs and hides the diagnosis in the percussion note.
Future alert: Effusion is stony dull; pneumothorax is hyperresonant — the note decides.
Correct: D) Exudate, because one positive Light criterion is sufficient
Concept: Light criteria — OR logic Recall
Why D: The source states exudate if any one Light criterion is positive — protein ratio >0.5, LDH ratio >0.6, or pleural LDH > two-thirds ULN.
Discriminator: The stem gives two sub-threshold values and one positive criterion — deliberately testing the 'any one is enough' rule.
| A) Transudate, because only one criterion is met | Light criteria are OR logic: any single positive criterion classifies the fluid as exudate. |
| B) Transudate unless all three criteria are met | Requiring all three criteria is the named trap; one positive criterion is enough. |
| C) Exudate only if the protein ratio is positive | All three criteria count equally; LDH-based criteria alone can also make an exudate. |
| E) Indeterminate without a serum albumin gradient | The albumin gradient is not part of the classic Light-criteria classification. |
Trap: The trap is 'you need all three'; Light criteria are OR logic by design.
Future alert: Any one positive Light criterion = exudate; never require all three.
Correct: E) Chest tube drainage plus antibiotics
Concept: Empyema — source control Interpretation
Why E: Pus with low pH/glucose and systemic toxicity is empyema, which needs drainage plus antibiotics — the source's one-line fatal-miss rule.
Discriminator: Frank pus + pH 7.0 + low glucose is the exact complicated-effusion/empyema cluster from the source table.
| A) Antibiotics alone with repeat imaging | Empyema needs drainage plus antibiotics; medical treatment alone is the named trap. |
| B) Switch antibiotics and observe | The infected pleural collection requires source control regardless of antibiotic choice. |
| C) Therapeutic thoracentesis only | A single tap does not drain an empyema; tube drainage is needed. |
| D) Pleurodesis as first-line therapy | Pleurodesis is for recurrent malignant effusions, not first-line empyema management. |
Trap: Antibiotics-only is the planted error; the source warns infected pleural space needs source control.
Future alert: Empyema = drain plus antibiotics; antibiotics alone never suffice.
Correct: A) Treat the heart failure; observe the effusions
Concept: Bilateral CHF effusion — transudate logic Interpretation
Why A: CHF causes bilateral transudative effusions; management is diuretics and heart-failure treatment, with the typical bilateral picture not requiring routine taps.
Discriminator: Bilateral effusions with a clear CHF story and no unilateral warning signs (fever, pleuritic pain, weight loss, hemoptysis) is the source's 'treat the cause' scenario.
| B) Diagnostic thoracentesis of both sides | Typical bilateral CHF effusions are not routinely tapped; the source's trap is tapping every bilateral CHF effusion. |
| C) Start antibiotics for parapneumonic effusion | No fever or pneumonia picture is present; transudates need underlying-cause treatment, not antibiotics. |
| D) Refer for pleurodesis | Recurrent malignant effusion is the pleurodesis indication, not a CHF transudate. |
| E) Classify both effusions with LDH and protein before treating | In established heart failure the effusions are transudates; the source's rule is to treat the failure, not to classify each side. |
Trap: The trap is tapping every bilateral CHF effusion or calling all effusions CHF; here the CHF picture is genuine.
Future alert: Typical bilateral CHF effusion = treat the HF; unilateral/atypical features force a diagnostic tap.
Correct: B) Immediate needle decompression of the right chest
Concept: Tension pneumothorax — decompress before imaging Analysis
Why B: Hypotension, distended neck veins, and tracheal deviation with absent unilateral breath sounds = tension pneumothorax; needle decompression comes before any imaging.
Discriminator: Shock + JVP + tracheal deviation + absent breath sounds is the exact tension cluster; the source says treat before CXR.
| A) Chest X-ray to confirm before treatment | Tension pneumothorax is a clinical diagnosis; waiting for imaging is the named fatal miss. |
| C) Oxygen and observation | Obstructive shock from tension pneumothorax needs decompression, not observation. |
| D) Urgent CT chest | Imaging delays the decompression that the clinical signs already mandate. |
| E) Three-sided occlusive dressing | That treats an open/sucking chest wound; this injury has no chest-wall wound described. |
Trap: The 'confirm with CXR first' reflex is the trap — the unstable chest is an action question, not an imaging question.
Future alert: Tension pneumothorax: decompress now, chest tube next; never wait for the CXR.
Correct: C) Occlusive dressing taped on three sides (or a vented chest seal)
Concept: Open pneumothorax — dressing Recall
Why C: Open pneumothorax is managed with an occlusive dressing taped on three sides or a vented chest seal, followed by a chest tube away from the wound.
Discriminator: A sucking chest wound is the source's open-pneumothorax trigger; the three-sided/vented concept is the tested rule.
| A) Fully seal the wound with an occlusive dressing on all four sides | A fully sealed wound can convert an open pneumothorax into a tension pneumothorax. |
| B) Pressure dressing to stop air movement | The goal is one-way escape of air, not stopping all air movement. |
| D) Leave the wound open until surgery | Immediate vented/three-sided coverage plus chest tube is the emergency step; an open sucking wound is not left bare. |
| E) Urgent CT chest before applying any dressing | A sucking chest wound needs immediate occlusive/three-sided sealing; imaging before dressing is the wrong order. |
Trap: Full sealing is the trap — the source warns a completely sealed wound converts open to tension.
Future alert: Open pneumothorax: three-sided/vented dressing, then chest tube; never fully seal.
Correct: D) Observation with oxygen if needed, based on symptoms and size
Concept: Stable small primary spontaneous pneumothorax Interpretation
Why D: Small stable primary spontaneous pneumothorax may be managed with observation/oxygen or aspiration depending on size and symptoms; overtreatment of tiny stable cases is the named trap.
Discriminator: Tall thin young patient + small stable pneumothorax is the exact primary-spontaneous profile from the source's terminology table.
| A) Immediate chest tube for all pneumothoraces | Small stable primary cases may be observed or aspirated; not every pneumothorax gets a tube. |
| B) Urgent needle decompression | Needle decompression is for tension physiology; this patient is stable with a small pneumothorax. |
| C) Admit for immediate surgery | Surgery is definitive repair for persistent/recurrent cases, not first-line small-stable management. |
| E) Immediate pleurodesis to prevent recurrence | Pleurodesis is for persistent or recurrent pneumothorax, not first-line management of a small stable primary episode. |
Trap: The reflex 'every pneumothorax needs a chest tube' is the overtreatment trap the source warns against.
Future alert: Small stable primary pneumothorax: observe/aspirate by size and symptoms; reserve the tube for large/symptomatic/secondary cases.
Correct: E) Insert a chest tube
Concept: Needle decompression — temporizing, not definitive Recall
Why E: Needle decompression is temporizing; the chest tube is the definitive treatment that follows it, per the source's management sequence.
Discriminator: The stem's 'clinical improvement after needle' is the setup — the question is what consolidates the rescue.
| A) Discharge home after symptom relief | Needle decompression buys time; without a chest tube the tension can recur. |
| B) Repeat needle decompression as needed | Repeated needles treat recurrence temporizingly; definitive management is the chest tube. |
| C) Observation in the emergency department for 24 hours | The needle alone is not definitive therapy for a tension pneumothorax. |
| D) High-flow oxygen and close monitoring alone | After temporizing needle decompression of a tension pneumothorax, a chest tube is mandatory; oxygen and monitoring alone risk re-accumulation. |
Trap: Treating the needle as the final step is the trap; the source pairs 'needle decompression → chest tube next' as the rule.
Future alert: Needle decompression is temporizing; chest tube is definitive.
Correct: A) NIV/BiPAP with controlled oxygen
Concept: COPD ABG — respiratory acidosis and support Analysis
Why A: Low pH with high PaCO2 in COPD is acidotic hypercapnic respiratory failure — NIV/BiPAP is first-line if suitable, with ABG recheck after starting.
Discriminator: pH 7.28 + PaCO2 76 + drowsy but rousable is the exact NIV-trigger combination; the elevated HCO3 marks chronicity (acute-on-chronic), not a metabolic primary.
| B) Intravenous sodium bicarbonate | The acidemia is ventilatory in origin; bicarbonate does not fix CO2 retention and is not the source's approach. |
| C) High-flow oxygen to correct PaO2 | The pH/CO2 pair makes this ventilatory failure; uncontrolled oxygen can worsen CO2 retention. |
| D) Immediate intubation | NIV is first-line when the patient is conscious, cooperative, and airway-protective; intubation is for NIV failure or contraindications. |
| E) Intravenous aminophylline to reverse respiratory fatigue | Theophylline is low-yield with a narrow therapeutic window and interactions; the pH 7.28 answer is NIV support, not aminophylline. |
Trap: The raised HCO3 tempts a metabolic reading; compensation for chronic hypercapnia explains it — the source calls this the acute-on-chronic trap.
Future alert: Low pH + high PaCO2 in COPD = NIV question; HCO3 elevation = compensation, not metabolic alkalosis.
Correct: B) Metabolic alkalosis with appropriate respiratory compensation
Concept: Vomiting — metabolic alkalosis with respiratory compensation Analysis
Why B: Vomiting/pyloric stenosis raises HCO3 (metabolic alkalosis); PaCO2 rises as respiratory compensation, so calling the high CO2 primary is wrong.
Discriminator: Repeated vomiting + high HCO3 + high PaCO2 with high pH is the source's exact metabolic-alkalosis-with-compensation stem.
| A) Respiratory acidosis with metabolic compensation | High PaCO2 here is the compensating response to a primary high-HCO3 state, not a primary respiratory problem. |
| C) Mixed respiratory and metabolic alkalosis | The PaCO2 is high, which is the opposite direction of an alkalotic respiratory process. |
| D) Metabolic alkalosis without compensation | The CO2 has risen in response to the high HCO3 — that is compensation, not its absence. |
| E) Metabolic acidosis with respiratory compensation | pH 7.51 with HCO3 42 is alkalosis, not acidosis — the interpretation hinges on the elevated PaCO2 as compensation. |
Trap: The trap is reading high PaCO2 as respiratory acidosis; the pH and the vomiting history decode it.
Future alert: Vomiting + high pH + high HCO3 = metabolic alkalosis; the high PaCO2 is compensation, not a second disorder.
Correct: C) Type 1 (hypoxemic) respiratory failure
Concept: Type 1 vs Type 2 respiratory failure Recall
Why C: Type 1 respiratory failure is hypoxemia with normal or low PaCO2 (V/Q mismatch, shunt, diffusion, pneumonia); Type 2 adds hypercapnia from alveolar hypoventilation.
Discriminator: PaO2 52 with a LOW PaCO2 and alkalotic pH is the Type 1 picture the source defines.
| A) Type 2 (hypercapnic) respiratory failure | Type 2 requires low PaO2 WITH high PaCO2; this PaCO2 is low. |
| B) Acute respiratory acidosis | The pH is alkalotic and CO2 is low — that is not respiratory acidosis. |
| D) Mixed type 1 and type 2 failure | Only one failure pattern is present: hypoxemia with a low/normal CO2. |
| E) Alveolar hypoventilation is the primary mechanism | PaCO2 is low, so hypoventilation is excluded; Type 1 failure is V/Q mismatch or shunt physiology. |
Trap: High CO2 is the knee-jerk 'respiratory failure' reflex; Type 1 is hypoxemia without hypercapnia.
Future alert: Type 1 = low PaO2, normal/low PaCO2; Type 2 = low PaO2 + high PaCO2.
Correct: D) Chronic respiratory acidosis with renal compensation
Concept: Compensation never overshoots Interpretation
Why D: Chronic respiratory acidosis shows a high HCO3 from renal compensation with pH closer to normal; compensation moves pH toward normal but never overshoots.
Discriminator: High PaCO2 with a near-normal pH and elevated HCO3 is the source's chronic-compensation pattern.
| A) Acute respiratory acidosis with no compensation | A near-normal pH with a markedly raised CO2 shows the kidneys have had time to retain bicarbonate — this is chronic, not acute. |
| B) Metabolic alkalosis with respiratory compensation | The primary driver is the high PaCO2; the HCO3 is the compensation, not the primary disorder. |
| C) Mixed acidosis and alkalosis | Compensation has moved the pH toward normal without overshooting — a single process, not a mixed disorder. |
| E) Respiratory alkalosis with metabolic compensation | PaCO2 66 is elevated — this is CO2 retention (respiratory acidosis); a near-normal pH with high HCO3 reflects renal compensation. |
Trap: High HCO3 alone is read as metabolic alkalosis — the trap is forgetting HCO3 also rises as renal compensation.
Future alert: A high HCO3 with high PaCO2 and near-normal pH = compensation for chronic respiratory acidosis, not primary metabolic alkalosis.
Correct: E) Systemic thrombolysis if no contraindication
Concept: Massive PE — thrombolysis decision Analysis
Why E: PE with hypotension/shock is massive/high-risk PE and becomes a thrombolysis (reperfusion) question if no contraindication exists.
Discriminator: BP 90/60 with a CTPA filling defect after long-haul flight is the source's 'BP is the pivot' stem.
| A) Anticoagulation alone with observation | Hypotension defines high-risk/massive PE; anticoagulation alone is insufficient when shock is present. |
| B) IV fluids and repeat imaging | Massive PE with shock is a reperfusion question; fluid resuscitation does not treat the obstruction. |
| C) Discharge on a DOAC | A shocked, filling-defect patient is not a discharge candidate. |
| D) Urgent inferior vena cava filter placement instead | An IVC filter prevents further emboli but does not treat the obstructing clot; the unstable patient needs systemic thrombolysis. |
Trap: The trap is treating massive PE like stable PE; hemodynamic instability changes anticoagulation into thrombolysis.
Future alert: In PE, BP decides: shock = thrombolysis if eligible; stable = anticoagulate.
Correct: A) PE is ruled out; no further imaging is needed
Concept: Low pre-test probability PE — D-dimer rule-out Interpretation
Why A: In low pre-test probability, a negative D-dimer rules out PE; D-dimer is a rule-out tool, not a confirmatory test.
Discriminator: Low Wells + negative D-dimer is the source's exact rule-out pairing; the mild short-trip story is deliberately low-risk.
| B) Proceed to CTPA for confirmation | A negative D-dimer in low pre-test probability rules out PE and avoids imaging. |
| C) Repeat the D-dimer in 12 hours | A single negative D-dimer in low probability is sufficient rule-out. |
| D) Start anticoagulation empirically | With PE ruled out by the low-probability/negative-D-dimer pair, anticoagulation is not indicated. |
| E) Admit for observation with serial troponins | A negative D-dimer at low pre-test probability completes rule-out; admission and cardiac monitoring are unnecessary. |
Trap: The trap is 'CTPA anyway' or reading a negative D-dimer as needing confirmation — the test is designed to avoid imaging.
Future alert: Low probability + negative D-dimer = PE ruled out; D-dimer never confirms.
Correct: B) Anticoagulation (DOAC or LMWH/UFH pathway)
Concept: Stable confirmed PE — anticoagulation Interpretation
Why B: Stable confirmed PE gets anticoagulation — DOACs commonly, LMWH in pregnancy/cancer contexts — with bleeding-risk and provoking-factor assessment.
Discriminator: Normotensive + confirmed filling defect is the stable-PE profile; no shock means no lysis.
| A) Systemic thrombolysis | Thrombolysis is for massive/high-risk PE with shock or selected deterioration — a stable segmental PE does not qualify. |
| C) Observation and repeat imaging in 2 weeks | Every confirmed stable PE is anticoagulated; observation is not an option. |
| D) Inferior vena cava filter alone | Filters are for anticoagulation contraindication/failure scenarios, not routine first-line therapy. |
| E) Aspirin monotherapy for 3 months | Aspirin is not adequate VTE treatment; anticoagulation (DOAC or LMWH/UFH pathway) is required for confirmed PE. |
Trap: Thrombolysis is the planted over-treatment; the source pairs 'CTPA filling defect, stable → anticoagulation, no shock, no lysis'.
Future alert: Stable confirmed PE = anticoagulation; reserve thrombolysis for shock.
Correct: C) Avoid estrogen-containing contraception permanently after VTE
Concept: OCP after VTE — estrogen contraindication Recall
Why C: Estrogen/OCP is a VTE risk factor and becomes contraindicated after PE; the source names combined OCP avoidance as the recurrence-prevention rule.
Discriminator: The PE-on-OCP story is the source's OCP/VTE contraindication stem.
| A) Combined OCP may resume after 6 months of anticoagulation | Prior VTE is an estrogen contraindication; combined OCPs are not restarted after VTE. |
| B) Progestin-only pills are equally contraindicated | The estrogen component is the VTE risk; progestin-only options are the safer pathway. |
| D) The OCP can resume if the D-dimer normalizes | D-dimer normalization does not lift the estrogen contraindication. |
| E) A copper intrauterine device is also contraindicated after VTE | The copper IUD is non-hormonal and safe after VTE — it remains an appropriate contraceptive option. |
Trap: The trap is 'enough time has passed, resume the OCP'; prior VTE is a standing estrogen contraindication.
Future alert: Estrogen/OCP after VTE = contraindicated; the source says avoid estrogen-containing contraception.
Correct: D) Small cell carcinoma (with SIADH)
Concept: Small cell lung cancer — SIADH Interpretation
Why D: Hyponatremia/SIADH in a smoker with a central hilar mass points to small cell lung cancer — the source pairs SIADH with small cell.
Discriminator: Hilar mass + smoker + severe hyponatremia is the exact paraneoplastic clue from the histology table.
| A) Squamous cell carcinoma | Squamous is central/cavitating and causes PTHrP hypercalcemia, not SIADH. |
| B) Adenocarcinoma | Adenocarcinoma is peripheral and non-smoker-associated, not the classic SIADH hilar tumor. |
| C) Pancoast tumor | Pancoast gives Horner syndrome and brachial plexus symptoms, not hyponatremia. |
| E) Carcinoid tumor | Carcinoids cause flushing, diarrhea, and serotonin excess — the smoker with a hilar mass and severe SIADH hyponatremia is small cell. |
Trap: The trap is treating SIADH as primary endocrine disease; the sodium is the cancer clue.
Future alert: Smoker + hilar mass + hyponatremia = small cell lung cancer with SIADH.
Correct: E) PTHrP secretion by squamous cell carcinoma
Concept: Squamous cell carcinoma — PTHrP hypercalcemia Interpretation
Why E: Central cavitating tumor with hypercalcemia and normal PTH is PTHrP-driven squamous cell carcinoma — the source's paraneoplastic match.
Discriminator: Central/cavitating + hypercalcemia + normal PTH is the exact squamous-clue pairing from the histology table.
| A) SIADH from small cell cancer | SIADH causes hyponatremia, not hypercalcemia. |
| B) Bone metastasis alone | The normal-PTH hypercalcemia with a cavitating central mass is the PTHrP paraneoplastic pattern. |
| C) Ectopic ACTH producing Cushing syndrome | Ectopic ACTH gives hypokalemia and Cushingoid features, not isolated hypercalcemia. |
| D) Primary hyperparathyroidism | The PTH is normal, excluding a parathyroid adenoma; the mass itself is the source. |
Trap: Small cell/SIADH is the planted misdirection; hypercalcemia belongs to squamous.
Future alert: Central cavitating mass + hypercalcemia = squamous/PTHrP; hyponatremia = small cell/SIADH.
Correct: A) High-dose dexamethasone and urgent MRI of the spine
Concept: Metastatic spinal cord compression Analysis
Why A: Back pain with weakness and bladder symptoms in known cancer is metastatic spinal cord compression: dexamethasone immediately, then urgent MRI and oncology/neurosurgery/radiotherapy pathway — never wait for complete paralysis.
Discriminator: Leg weakness + urinary retention + known lung cancer is the source's exact cord-compression cluster.
| B) Outpatient follow-up with analgesia | Back pain plus weakness/bladder symptoms in known cancer is cord compression until proven otherwise — the source names outpatient analgesia a fatal miss. |
| C) Urgent MRI after starting physiotherapy | Steroids and imaging are the emergency pathway; physiotherapy is not the first step. |
| D) Spinal X-ray series only | Plain X-rays do not assess cord compression; urgent MRI is required. |
| E) Immediate radiotherapy alone, deferring imaging | Cord compression must be confirmed and localized by urgent MRI before treatment; empiric radiation without imaging is unsafe. |
Trap: 'Routine musculoskeletal back pain' is the planted misread; bladder/weakness signs make it an emergency.
Future alert: Cancer + back pain + weakness/bladder signs = cord compression: dexamethasone + urgent MRI now.
Correct: B) Pancoast (superior sulcus) tumor
Concept: Pancoast tumor — Horner syndrome Recall
Why B: An apical mass causing shoulder pain with Horner syndrome (ptosis, miosis, anhidrosis) and lower brachial plexus symptoms is the Pancoast tumor signature.
Discriminator: Apical mass + Horner + shoulder/arm pain is the exact Pancoast cluster from the histology table.
| A) Small cell lung cancer with SIADH | SIADH small cell gives hyponatremia, not Horner syndrome from an apical mass. |
| C) Metastatic spinal cord compression | Cord compression gives back pain with leg weakness and bladder symptoms, not Horner. |
| D) Pulmonary embolism | PE gives sudden pleuritic dyspnea with VTE risk factors, not shoulder pain with Horner. |
| E) Simple cervical radiculopathy | The apical mass with Horner localizes to the superior sulcus, not isolated nerve root disease. |
Trap: The trap is calling it shoulder disease; Horner plus the apical lesion seals the Pancoast answer.
Future alert: Apical mass + Horner = Pancoast tumor.
Correct: C) High-resolution CT (HRCT) of the chest
Concept: Bronchiectasis — HRCT diagnosis Interpretation
Why C: Daily purulent sputum with recurrent infections, clubbing, and signet-ring dilated bronchi on HRCT defines bronchiectasis; HRCT is the key diagnostic test.
Discriminator: Years of large-volume purulent sputum + recurrent infections + clubbing is the source's bronchiectasis trigger.
| A) Chest X-ray | CXR can suggest but is not the diagnostic test; the source names HRCT as the key. |
| B) Spirometry alone | Spirometry may show obstruction but does not confirm bronchial dilation. |
| D) Sputum culture alone | Cultures guide antibiotics but do not diagnose bronchiectasis. |
| E) Sweat chloride | Sweat chloride tests for CF, not bronchiectasis as a general diagnosis. |
Trap: The trap is CXR-as-diagnosis; the source explicitly warns CXR can suggest but HRCT clinches it.
Future alert: Chronic large-volume purulent sputum + recurrent infections = bronchiectasis; confirm with HRCT.
Correct: D) Primary ciliary dyskinesia (Kartagener syndrome)
Concept: Kartagener syndrome — situs inversus clue Interpretation
Why D: Sinusitis + bronchiectasis + infertility with situs inversus is Kartagener syndrome (primary ciliary dyskinesia) — the source pairs these four exactly.
Discriminator: Dextrocardia/situs inversus is the single decisive clue that separates PCD from CF in the source's trap-pair table.
| A) Cystic fibrosis | CF gives pancreatic insufficiency and thick secretions; situs inversus is not its marker. |
| B) Chronic asthma | Asthma is episodic wheeze, not sinusitis with situs inversus and infertility. |
| C) Alpha-1 antitrypsin deficiency | A1AT gives basilar emphysema and liver disease, not situs inversus. |
| E) Tuberculosis | TB gives apical cavitation with constitutional symptoms, not situs inversus. |
Trap: CF is the camouflage; situs inversus points to ciliary dyskinesia, not CFTR disease.
Future alert: Sinusitis + situs inversus + infertility = Kartagener/primary ciliary dyskinesia.
Correct: E) Sweat chloride or CFTR genetic testing
Concept: Cystic fibrosis — adult presentation Interpretation
Why E: Recurrent infections with pancreatic insufficiency points to cystic fibrosis — sweat chloride/CFTR testing is the diagnostic clue, and milder CF can present in adults.
Discriminator: Recurrent sinopulmonary infections + pancreatic insufficiency + bronchiectasis is the source's CF cluster, including the adult-presentation warning.
| A) HRCT alone | HRCT shows the bronchiectasis but does not establish CF as the cause. |
| B) Sputum AFB smear | AFB tests for tuberculosis, not CF. |
| C) Serum alpha-1 antitrypsin level | A1AT testing addresses emphysema/liver disease, not pancreatic-insufficiency lung disease. |
| D) Nasal nitric oxide testing for primary ciliary dyskinesia | PCD/Kartagener causes bronchiectasis with otitis, sinusitis, and situs inversus — this man's pancreatitis and steatorrhea point to CF and sweat chloride/CFTR testing. |
Trap: The trap is 'CF only in children'; the source warns milder CF surfaces in adults with bronchiectasis, infertility, sinus disease, or pancreatitis.
Future alert: Recurrent lung infections + pancreatic insufficiency = CF; confirm with sweat chloride/CFTR.
Correct: A) Stabilize the airway as an emergency (positioning, suction, urgent bronchial artery/airway team involvement)
Concept: Massive hemoptysis — airway emergency Recall
Why A: Massive hemoptysis in bronchiectasis reflects inflamed bronchial arteries and is an airway emergency requiring urgent stabilization — the source's one-line warning.
Discriminator: Sudden large-volume hemoptysis with airway compromise is exactly the emergency the source flags.
| B) Observe in the ward overnight | Massive hemoptysis in bronchiectasis is an airway emergency; overnight observation is the fatal miss. |
| C) Start routine antibiotics and recheck in the morning | Antibiotics do not control bleeding from inflamed bronchial arteries. |
| D) Arrange outpatient HRCT for next week | This is an immediate stabilization problem, not an outpatient imaging case. |
| E) Transfusion of packed red cells alone | Transfusion supports circulation but does not protect the airway — large-volume hemoptysis demands airway control and urgent bleeding-control measures. |
Trap: Treating it as an outpatient infection exacerbation is the plant; bleeding severity overrides routine care.
Future alert: Massive hemoptysis = airway emergency: stabilize and escalate, never observe overnight.
Correct: B) Restrictive lung disease (interstitial pattern)
Concept: ILD — restrictive PFT pattern Interpretation
Why B: ILD produces a restrictive pattern: low FVC/TLC with normal or high FEV1/FVC — the source's exact definition and its named trap (calling restriction COPD).
Discriminator: Dry cough + fine crackles + low FVC/TLC with normal/high ratio is the restrictive cluster from the source.
| A) Obstructive lung disease | Obstruction shows a LOW FEV1/FVC; a normal-to-high FEV1/FVC with low volumes is the restrictive signature. |
| C) Mixed obstructive-restrictive disease | The normal-to-high FEV1/FVC argues against a clinically significant obstructive component. |
| D) Normal spirometry | Low FVC and TLC with preserved FEV1/FVC is abnormal and restrictive. |
| E) Isolated small-airway disease | Small-airway disease is an obstructive concept; low volumes with high ratio are restrictive. |
Trap: The trap is reading 'lung disease = obstruction'; restriction preserves or raises the FEV1/FVC.
Future alert: Restrictive ILD = low TLC/FVC with normal or high FEV1/FVC — never call it COPD.
Correct: C) Idiopathic pulmonary fibrosis (UIP)
Concept: UIP/IPF — honeycombing Recall
Why C: Subpleural basal honeycombing with progressive dyspnea and clubbing is the UIP/IPF HRCT signature — the source pairs honeycombing with UIP/IPF.
Discriminator: Bibasal subpleural honeycombing without an exposure or systemic story is the source's IPF clue.
| A) Silicosis | Silicosis gives upper-lobe nodules and eggshell nodes with a mining history. |
| B) Hypersensitivity pneumonitis | HP follows bird/mold antigen exposure with ground glass/centrilobular nodules. |
| D) Asbestosis alone | Asbestosis shows lower-lobe fibrosis with pleural plaques, but classic UIP honeycombing without exposure points to IPF. |
| E) Sarcoidosis | Sarcoid classically involves hilar nodes and an upper-lobe pattern. |
Trap: Occupational disease is the camouflage; the lobar pattern and exposure history separate them.
Future alert: Subpleural basal honeycombing = UIP/IPF; upper-lobe nodules = pneumoconiosis/sarcoid.
Correct: D) Asbestosis
Concept: Asbestosis — exposure and pattern Interpretation
Why D: Shipyard/insulation exposure with lower-lobe fibrosis and pleural plaques is asbestosis; the source pairs the exposure, the lobe pattern, and the plaques.
Discriminator: Retired shipyard worker + lower-lobe fibrosis + pleural plaques is the exact asbestosis cluster.
| A) Silicosis | Silica exposure gives upper-lobe nodules and eggshell nodes with a mining/sandblasting history. |
| B) Coal worker pneumoconiosis | Coal dust gives upper-lobe nodules/PMF, not pleural plaques with lower-lobe fibrosis. |
| C) Hypersensitivity pneumonitis | HP follows birds/moldy hay with ground glass, not shipyard exposure with pleural plaques. |
| E) Idiopathic pulmonary fibrosis | The shipyard history and pleural plaques make asbestos exposure the answer over IPF. |
Trap: Silicosis is the camouflage; lobe pattern (lower vs upper) and plaques (asbestos) separate them.
Future alert: Pleural plaques + lower-lobe fibrosis + shipyard history = asbestosis; watch for mesothelioma/bronchogenic cancer risk.
Correct: E) Identify and remove the antigen (pigeon exposure)
Concept: Hypersensitivity pneumonitis — antigen removal Interpretation
Why E: Hypersensitivity pneumonitis from bird/farmer/humidifier exposure is treated by identifying and removing the antigen; steroids help significant inflammatory disease.
Discriminator: Pigeons + dry cough/dyspnea + ground glass is the source's HP exposure clue.
| A) Start antifibrotic therapy | Antifibrotics are for progressive IPF; the first move in HP is antigen removal. |
| B) Bronchial thermoplasty | Thermoplasty is an asthma procedure, not an ILD therapy. |
| C) Pleurodesis | Pleurodesis treats recurrent effusions, not parenchymal lung disease. |
| D) Continue exposure and add long-term oral steroids | Antigen removal is the cornerstone; steroids are an adjunct for significant inflammatory disease, never a substitute for removing the bird exposure. |
Trap: The trap is skipping the exposure history and treating it as idiopathic fibrosis.
Future alert: Bird/farmer/mold exposure + ILD = hypersensitivity pneumonitis: remove the antigen first.
Correct: A) Goodpasture syndrome (anti-GBM disease)
Concept: Goodpasture syndrome — anti-GBM Interpretation
Why A: Hemoptysis with nephritic urine and positive anti-GBM is Goodpasture syndrome — anti-GBM antibodies attack type IV collagen in lung and kidney basement membranes.
Discriminator: Hemoptysis + RBC casts + positive anti-GBM is the source's three-clue Goodpasture stem.
| B) Granulomatosis with polyangiitis (GPA) | GPA classically shows ENT disease with c-ANCA/PR3; the anti-GBM antibody is decisive here. |
| C) Pulmonary embolism | PE causes pleuritic dyspnea but not nephritic urine with RBC casts. |
| D) Tuberculosis | TB causes hemoptysis but not hematuria with RBC casts and anti-GBM positivity. |
| E) Systemic lupus erythematosus | SLE gives low complement and anti-dsDNA, not positive anti-GBM. |
Trap: GPA is the camouflage; the antibody test, not the bleeding, is decisive.
Future alert: Hemoptysis + hematuria/RBC casts + anti-GBM = Goodpasture.
Correct: B) Granulomatosis with polyangiitis (GPA)
Concept: GPA — ENT clue and c-ANCA Interpretation
Why B: ENT disease (sinusitis, nasal crusting) with lung-kidney involvement and c-ANCA/PR3 is GPA — the source pairs ENT clues with c-ANCA explicitly.
Discriminator: Sinusitis + nasal crusting + hemoptysis + hematuria + c-ANCA is the source's GPA cluster versus Goodpasture.
| A) Goodpasture syndrome | Goodpasture is anti-GBM with no ENT granulomatous story; this patient's sinusitis and c-ANCA point to GPA. |
| C) Microscopic polyangiitis | MPA is p-ANCA/MPO and usually lacks the ENT granulomatous picture. |
| D) Systemic lupus erythematosus | SLE shows low complement and anti-dsDNA, not c-ANCA with necrotizing ENT disease. |
| E) Pulmonary embolism | PE causes respiratory symptoms without sinusitis, RBC casts, or ANCA positivity. |
Trap: Goodpasture is the reflex for hemoptysis + nephritis; the ENT story hands it to GPA.
Future alert: ENT disease + c-ANCA/PR3 + lung/kidney = GPA; Goodpasture = anti-GBM without ENT disease.
Correct: C) Systemic lupus erythematosus with nephritis and pulmonary involvement
Concept: SLE pulmonary-renal — serology Analysis
Why C: SLE pulmonary-renal disease is immune-complex driven with low complement and anti-dsDNA, plus systemic lupus clues (arthralgias, oral ulcers) — the source's serology table.
Discriminator: Low C3/C4 + anti-dsDNA + systemic lupus features is the SLE-first serology cluster from the source table.
| A) Goodpasture syndrome | Goodpasture is anti-GBM positive; this patient's low complement and anti-dsDNA point to SLE. |
| B) Granulomatosis with polyangiitis | GPA is c-ANCA/PR3 with ENT disease; lupus serology does not fit. |
| D) Microscopic polyangiitis | MPA is p-ANCA/MPO and lacks the lupus systemic features. |
| E) Tuberculosis | TB causes constitutional symptoms and hemoptysis but not low complement with anti-dsDNA. |
Trap: The trap is defaulting to ANCA disease whenever lungs and kidneys are both involved; the serology pattern redirects to SLE.
Future alert: Hemoptysis + nephritis + low complement/anti-dsDNA = SLE pulmonary-renal disease, not ANCA vasculitis.
Correct: D) Tuberculosis
Concept: Hemoptysis differential — apical cavity pattern Interpretation
Why D: The final hemoptysis table maps chronic cough + weight loss + night sweats + apical cavity to TB — the constitutional cluster and apical distribution are the discriminators.
Discriminator: Apical cavity plus night sweats/weight loss in a young patient is the exact TB row of the source's hemoptysis differential.
| A) Lung cancer | Cancer fits an older smoker with weight loss and a persistent mass/non-resolving opacity, not night sweats with an apical cavity in a young patient. |
| B) Bronchiectasis | Bronchiectasis gives daily purulent sputum with recurrent infections and clubbing, not constitutional symptoms with an apical cavity. |
| C) Pulmonary embolism | PE gives sudden pleuritic pain after a flight/OCP, not chronic weight loss with night sweats. |
| E) Pneumonia | Pneumonia fits fever, cough, and consolidation with an infiltrate, not a chronic apical cavity with weight loss. |
Trap: Lung cancer is the camouflage; age and the apical-cavity-plus-constitution pattern hand it to TB.
Future alert: Chronic cough + night sweats + weight loss + apical cavity = TB; smoker-mass = cancer; purulent daily sputum = bronchiectasis.
Correct: E) Treat as life-threatening asthma with ICU/intubation preparation
Concept: Fatal-miss list — silent chest reflex Analysis
Why E: The fatal-miss table maps 'silent chest in asthma' to 'treat as life-threatening with ICU/intubation preparation' — less wheeze can mean less airflow.
Discriminator: Quieter chest + drowsiness + rising PaCO2 is the exact fatal-miss cluster of the final table.
| A) Reassure the family that the wheeze is resolving | Less wheeze can mean less airflow; the source names silent chest a red flag, not a reassuring finding. |
| B) Discharge with oral steroids | A quiet, drowsy, CO2-rising asthmatic is not a discharge candidate. |
| C) Repeat salbutamol and observe for 2 hours | Routine repeat bronchodilators without escalation underplays impending respiratory arrest. |
| D) Order a chest X-ray before any escalation | The life-threatening tier demands immediate treatment/intubation preparation, not imaging first. |
Trap: The 'wheeze is resolving' read is the trap the source pins as the asthma fatal miss.
Future alert: Silent/quiet chest in acute asthma = impending arrest: act like it, escalate now.
Correct: A) Drain the pleural space and give antibiotics
Concept: Empyema from the fatal-miss list — source control Interpretation
Why A: The final fatal-miss table states: empyema → drain plus antibiotics — infected pleural space needs source control.
Discriminator: Recurrent fever after pneumonia with pus at thoracentesis is the empyema row of the fatal-miss list.
| B) Antibiotics alone with close observation | The fatal-miss list pairs empyema with 'drain plus antibiotics'; medical therapy alone is the named miss. |
| C) Anti-tuberculous therapy only | Pus with pneumonia is empyema, not tuberculous effusion. |
| D) Repeat thoracentesis weekly | A single-tap strategy does not provide the source control an empyema needs. |
| E) Pleurodesis first | Pleurodesis is for recurrent malignant effusions, not first-line empyema management. |
Trap: Antibiotics-only is the planted error; the list names it the empyema fatal miss.
Future alert: Empyema = drainage plus antibiotics; never antibiotics alone.
This MedCORE is not a medical textbook. It is only designed for rapid, last-minute recall and should be treated like a high-yield cheat sheet, not a complete learning resource. Use it to memorize critical algorithms and recognition patterns.